<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:gnpx="http://www.genprex.com/20250930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gnpx-20250930.xsd" xlink:type="simple"/>
    <context id="d_2025-01-01_2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2025-11-13</instant>
        </period>
    </context>
    <context id="i_2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-ExcludingElocPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:ExcludingElocPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-ExcludingElocPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:ExcludingElocPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2025ElocFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2025ElocFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-02-02_2024-02-02_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">gnpx:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-02</startDate>
            <endDate>2024-02-02</endDate>
        </period>
    </context>
    <context id="d_2025-10-21_2025-10-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">gnpx:ReverseStockSplitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-21</startDate>
            <endDate>2025-10-21</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="d_2024-03-21_2024-03-21_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantAndCommonWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantAndCommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="d_2024-03-01_2024-03-31_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-21_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:AmendedRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="i_2023-03-31_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:AmendedRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-07-31_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:AmendedRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="i_2024-03-21_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:AmendedRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-12-13_2023-12-13_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2023AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-13</startDate>
            <endDate>2023-12-13</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2023AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2023AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-06-11_2025-06-11_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2025ElocFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-11</startDate>
            <endDate>2025-06-11</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2025ElocFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">gnpx:ElocDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">gnpx:ElocDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">gnpx:ElocDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">gnpx:ElocDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">gnpx:ElocDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">gnpx:ElocDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">gnpx:ElocDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">gnpx:ElocDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2025ElocFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_StatementClassOfStockAxis-CommitmentSharesMember_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gnpx:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2025ElocFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2023AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-ServiceProvidersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ServiceProvidersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2023AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-March2024RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:March2024RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024CommonWarrantsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-March2024CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:March2024CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:AmendedRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:AmendedRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_ClassOfWarrantOrRightAxis-VestingOfWarrantsForServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:VestingOfWarrantsForServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-VestingOfWarrantsForServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:VestingOfWarrantsForServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:OutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:OutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:OutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-03</instant>
        </period>
    </context>
    <context id="d_2018-04-03_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="d_2025-08-15_2025-08-15_PlanNameAxis-Amended2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:Amended2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-15</startDate>
            <endDate>2025-08-15</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-01-01_PlanNameAxis-Amended2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:Amended2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-01-01_PlanNameAxis-Amended2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:Amended2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_PlanNameAxis-Amended2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:Amended2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-03</instant>
        </period>
    </context>
    <context id="i_2025-09-30_PlanNameAxis-The2018EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_StatementEquityComponentsAxis-CommonStockMember_TitleOfIndividualAxis-BoardMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:BoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember_TitleOfIndividualAxis-ExecutivesEmployeesAndNonemployeeDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ExecutivesEmployeesAndNonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2025-09-30_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:PerformancebasedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="d_2018-07-01_2018-07-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="d_2022-09-30_2022-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-06_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-06</endDate>
        </period>
    </context>
    <context id="d_2024-06-07_2024-06-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-07</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-12-31</instant>
        </period>
    </context>
    <context id="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-01-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-03_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-03</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-09-30_CounterpartyNameAxis-NationalInstituteOfHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-04-25_CounterpartyNameAxis-NyuMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NyuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="i_2025-04-25_CounterpartyNameAxis-NyuMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NyuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="i_2025-04-25_CounterpartyNameAxis-NyuMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NyuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_CounterpartyNameAxis-NyuMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NyuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfMichiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfMichiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfMichiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_CounterpartyNameAxis-UniversityOfMichiganMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfMichiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfMichiganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-17</instant>
        </period>
    </context>
    <context id="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-17</instant>
        </period>
    </context>
    <context id="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-17</instant>
        </period>
    </context>
    <context id="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-17</instant>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UthealthHoustonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-02</instant>
        </period>
    </context>
    <context id="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UthealthHoustonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-02</instant>
        </period>
    </context>
    <context id="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UthealthHoustonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-02</instant>
        </period>
    </context>
    <context id="d_2025-05-02_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UthealthHoustonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-02</startDate>
            <endDate>2025-05-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UthealthHoustonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:DevelopmentAndManufacturingOfGMPGradeMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2024-06-30_2024-06-30_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:DevelopmentAndManufacturingOfGMPGradeMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:DevelopmentAndManufacturingOfGMPGradeMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:DevelopmentAndManufacturingOfGMPGradeMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2025-10-01_2025-10-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-01</endDate>
        </period>
    </context>
    <context id="d_2025-10-01_2025-10-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2025ElocFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-01</endDate>
        </period>
    </context>
    <context id="d_2025-10-24_2025-10-24_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2024RegisteredDirectOffering1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:October2024RegisteredDirectOffering1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-24</startDate>
            <endDate>2025-10-24</endDate>
        </period>
    </context>
    <context id="i_2025-10-24_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2024RegisteredDirectOffering1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:October2024RegisteredDirectOffering1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="i_2025-10-24_ClassOfWarrantOrRightAxis-October2025PrivateWarrants1Member_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:October2025PrivateWarrants1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="i_2025-10-24_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="d_2025-10-24_2025-10-24_ClassOfWarrantOrRightAxis-October2025PrivateWarrants1Member_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:October2025PrivateWarrants1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-24</startDate>
            <endDate>2025-10-24</endDate>
        </period>
    </context>
    <context id="d_2025-10-29_2025-10-29_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2025RegisteredDirectOffering2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:October2025RegisteredDirectOffering2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-29</startDate>
            <endDate>2025-10-29</endDate>
        </period>
    </context>
    <context id="i_2025-10-29_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2025RegisteredDirectOffering2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:October2025RegisteredDirectOffering2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-29</instant>
        </period>
    </context>
    <context id="i_2025-10-29_ClassOfWarrantOrRightAxis-October2025PrivateWarrants2Member_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:October2025PrivateWarrants2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-29</instant>
        </period>
    </context>
    <context id="i_2025-10-29_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-29</instant>
        </period>
    </context>
    <context id="d_2025-10-29_2025-10-29_ClassOfWarrantOrRightAxis-October2025PrivateWarrants2Member_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:October2025PrivateWarrants2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-29</startDate>
            <endDate>2025-10-29</endDate>
        </period>
    </context>
    <context id="d_2025-11-10_2025-11-10_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2023AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <context id="d_2025-10-01_2025-11-14_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2023AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-11-14</endDate>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2025-01-01_2025-09-30"
      id="thunderdome-EntityCentralIndexKey">0001595248</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2025-01-01_2025-09-30"
      id="thunderdome-EntityRegistrantName">Genprex, Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2025-01-01_2025-09-30" id="ixv-6798">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2025-01-01_2025-09-30" id="ixv-6799">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2025-01-01_2025-09-30" id="ixv-6800">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2025-01-01_2025-09-30" id="ixv-6801">2025</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-09-30"
      id="c138416620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2024-12-31"
      id="c138416621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416625"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416626"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416627"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416628"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c138416629"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c138416631"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c138416630"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c138416632"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416635"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416636"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416637"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416638"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416639"
      unitRef="Share">1004247</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416641"
      unitRef="Share">1004247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416640"
      unitRef="Share">217234</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416642"
      unitRef="Share">217234</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2025-09-30_RangeAxis-MinimumMember"
      id="c138417188">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2025-09-30_RangeAxis-MaximumMember"
      id="c138417189">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417199"
      unitRef="USD">243000</us-gaap:DerivativeLiabilities>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024CommonWarrantsMember"
      id="c138417252">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember"
      id="c138417259">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417343"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417345"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c138417346"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c138417347"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417349"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417351"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2025-07-01_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="-3"
      id="c138417360"
      unitRef="Share">0</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2025-01-01_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="-3"
      id="c138417361"
      unitRef="Share">0</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <gnpx:WarrantsOrRightsCancelledDuringPeriod
      contextRef="d_2025-01-01_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417363"
      unitRef="Share">25</gnpx:WarrantsOrRightsCancelledDuringPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-07-01_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="-3"
      id="c138417365"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="-3"
      id="c138417366"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2024-07-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="-3"
      id="c138417377"
      unitRef="Share">0</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember"
      id="c138417390">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember"
      id="c138417399">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2025-01-01_2025-09-30" id="c138417458">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-07-01_2025-09-30"
      decimals="-3"
      id="c138417464"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-09-30"
      decimals="-3"
      id="c138417465"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-07-01_2024-09-30"
      decimals="-3"
      id="c138417471"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-09-30"
      decimals="-3"
      id="c138417472"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417631"
      unitRef="USDPerShare">6081.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c138417633"
      unitRef="USDPerShare">6054.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c138417639"
      unitRef="USDPerShare">6081.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c138417641"
      unitRef="USDPerShare">6061.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c138417647"
      unitRef="USDPerShare">6081.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c138417649"
      unitRef="USDPerShare">6074.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-09-30"
      decimals="2"
      id="c138417655"
      unitRef="USDPerShare">6081.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-09-30"
      decimals="2"
      id="c138417657"
      unitRef="USDPerShare">6079.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-09-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="-3"
      id="c138417530"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember"
      decimals="INF"
      id="c138417531"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-07-01_2025-09-30_CounterpartyNameAxis-UniversityOfMichiganMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="-3"
      id="c138417795"
      unitRef="USD">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-07-01_2025-09-30_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="-3"
      id="c138417817"
      unitRef="USD">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-01-01_2025-09-30_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember"
      decimals="-3"
      id="c138417833"
      unitRef="USD">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2024-01-01_2024-09-30_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember"
      decimals="-3"
      id="c138417838"
      unitRef="USD">0</us-gaap:CostsAndExpenses>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2025-07-01_2025-09-30" id="c138417996">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2025-07-01_2025-09-30" id="c138417997">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2025-07-01_2025-09-30" id="c138417998">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2025-07-01_2025-09-30" id="c138417999">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType contextRef="d_2025-01-01_2025-09-30" id="ixv-8656">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2025-01-01_2025-09-30" id="ixv-8657">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2025-01-01_2025-09-30" id="ixv-8658">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2025-01-01_2025-09-30" id="ixv-8659">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2025-01-01_2025-09-30" id="ixv-8660">001-38244</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2025-01-01_2025-09-30" id="ixv-8661">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2025-01-01_2025-09-30" id="ixv-8662">90-0772347</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2025-01-01_2025-09-30" id="ixv-8663">3300 Bee Cave Road, #650-227</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2025-01-01_2025-09-30" id="ixv-8664">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2025-01-01_2025-09-30" id="ixv-8665">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2025-01-01_2025-09-30" id="ixv-8666">78746</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2025-01-01_2025-09-30" id="ixv-8667">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2025-01-01_2025-09-30" id="ixv-8668">537-7997</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2025-01-01_2025-09-30" id="ixv-8669">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2025-01-01_2025-09-30" id="ixv-8670">GNPX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2025-01-01_2025-09-30" id="ixv-8671">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2025-01-01_2025-09-30" id="ixv-8672">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2025-01-01_2025-09-30" id="ixv-8673">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2025-01-01_2025-09-30" id="ixv-8674">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2025-01-01_2025-09-30" id="ixv-8675">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2025-01-01_2025-09-30" id="ixv-8676">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2025-01-01_2025-09-30" id="ixv-8677">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2025-11-13"
      decimals="INF"
      id="ixv-8678"
      unitRef="Share">2270346</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416590"
      unitRef="USD">1103315</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416591"
      unitRef="USD">1601660</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416592"
      unitRef="USD">611786</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416593"
      unitRef="USD">475807</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416594"
      unitRef="USD">1715101</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416595"
      unitRef="USD">2077467</us-gaap:AssetsCurrent>
    <gnpx:ResearchAndDevelopmentAssetsNoncurrent
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416597"
      unitRef="USD">1847412</gnpx:ResearchAndDevelopmentAssetsNoncurrent>
    <gnpx:ResearchAndDevelopmentAssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416598"
      unitRef="USD">2046858</gnpx:ResearchAndDevelopmentAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416599"
      unitRef="USD">1847412</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416600"
      unitRef="USD">2046858</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416601"
      unitRef="USD">3562513</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416602"
      unitRef="USD">4124325</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416605"
      unitRef="USD">1619446</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416606"
      unitRef="USD">1074295</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416607"
      unitRef="USD">932260</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416608"
      unitRef="USD">1429875</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416609"
      unitRef="USD">2551706</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416610"
      unitRef="USD">2504170</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416615"
      unitRef="USD">243000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416616"
      unitRef="USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:Liabilities
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416617"
      unitRef="USD">2794706</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416618"
      unitRef="USD">2504170</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416623"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416624"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416633"
      unitRef="USD">1004</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416634"
      unitRef="USD">217</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416643"
      unitRef="USD">168004988</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416644"
      unitRef="USD">156419381</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416645"
      unitRef="USD">-167238185</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416646"
      unitRef="USD">-154799443</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416647"
      unitRef="USD">767807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416648"
      unitRef="USD">1620155</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416649"
      unitRef="USD">3562513</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416650"
      unitRef="USD">4124325</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Depreciation
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416664"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416665"
      unitRef="USD">1272</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416666"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416667"
      unitRef="USD">6230</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416668"
      unitRef="USD">2192881</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416669"
      unitRef="USD">2756081</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416670"
      unitRef="USD">7232370</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416671"
      unitRef="USD">7696983</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416672"
      unitRef="USD">1153032</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416673"
      unitRef="USD">1566085</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416674"
      unitRef="USD">4764617</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416675"
      unitRef="USD">9135225</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416676"
      unitRef="USD">3345913</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416677"
      unitRef="USD">4323438</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416678"
      unitRef="USD">11996987</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416679"
      unitRef="USD">16838438</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416680"
      unitRef="USD">-3345913</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416681"
      unitRef="USD">-4323438</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416682"
      unitRef="USD">-11996987</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416683"
      unitRef="USD">-16838438</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416684"
      unitRef="USD">2405</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416685"
      unitRef="USD">8080</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416686"
      unitRef="USD">14056</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416687"
      unitRef="USD">58851</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416688"
      unitRef="USD">-455549</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416689"
      unitRef="USD">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416690"
      unitRef="USD">-455549</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416691"
      unitRef="USD">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416692"
      unitRef="USD">-183</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416693"
      unitRef="USD">-629</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416694"
      unitRef="USD">-262</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416695"
      unitRef="USD">-1115</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416696"
      unitRef="USD">-3799240</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416697"
      unitRef="USD">-4315987</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416698"
      unitRef="USD">-12438742</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416699"
      unitRef="USD">-16780702</us-gaap:NetIncomeLoss>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416700"
      unitRef="USD">-0</gnpx:DeemedDividendWarrantModification>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416701"
      unitRef="USD">-0</gnpx:DeemedDividendWarrantModification>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416702"
      unitRef="USD">-0</gnpx:DeemedDividendWarrantModification>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416703"
      unitRef="USD">277119</gnpx:DeemedDividendWarrantModification>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416704"
      unitRef="USD">-3799240</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416705"
      unitRef="USD">-4315987</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416706"
      unitRef="USD">-12438742</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416707"
      unitRef="USD">-17057821</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416708"
      unitRef="USDPerShare">-5</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416709"
      unitRef="USDPerShare">-61.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416710"
      unitRef="USDPerShare">-23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416711"
      unitRef="USDPerShare">-344.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416712"
      unitRef="Share">760502</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416713"
      unitRef="Share">70013</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416714"
      unitRef="Share">540910</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416715"
      unitRef="Share">48651</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416726"
      unitRef="Share">217234</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416727"
      unitRef="USD">217</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416728"
      unitRef="USD">156419381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416729"
      unitRef="USD">-154799443</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416730"
      unitRef="USD">1620155</us-gaap:StockholdersEquity>
    <gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416731"
      unitRef="Share">265574</gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416732"
      unitRef="USD">266</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416733"
      unitRef="USD">6027837</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416734"
      unitRef="USD">0</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138416735"
      unitRef="USD">6028103</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416736"
      unitRef="Share">100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416737"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416738"
      unitRef="USD">4505</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416739"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138416740"
      unitRef="USD">4505</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416741"
      unitRef="Share">200</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416742"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416743"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416744"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138416745"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416747"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416748"
      unitRef="USD">179693</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416749"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138416750"
      unitRef="USD">179693</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416752"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416753"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416754"
      unitRef="USD">-3964601</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138416755"
      unitRef="USD">-3964601</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416756"
      unitRef="Share">483108</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416757"
      unitRef="USD">483</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416758"
      unitRef="USD">162631416</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416759"
      unitRef="USD">-158764044</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c138416760"
      unitRef="USD">3867855</us-gaap:StockholdersEquity>
    <gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416761"
      unitRef="Share">154393</gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416762"
      unitRef="USD">154</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416763"
      unitRef="USD">1742587</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416764"
      unitRef="USD">0</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138416765"
      unitRef="USD">1742741</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416766"
      unitRef="Share">23837</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416767"
      unitRef="USD">24</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416768"
      unitRef="USD">366678</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416769"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138416770"
      unitRef="USD">366702</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416771"
      unitRef="Share">1585</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416772"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416773"
      unitRef="USD">-2</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416774"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138416775"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416777"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416778"
      unitRef="USD">88799</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416779"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138416780"
      unitRef="USD">88799</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416782"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416783"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416784"
      unitRef="USD">-4674901</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138416785"
      unitRef="USD">-4674901</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416786"
      unitRef="Share">662923</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416787"
      unitRef="USD">663</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416788"
      unitRef="USD">164829478</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416789"
      unitRef="USD">-163438945</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c138416790"
      unitRef="USD">1391196</us-gaap:StockholdersEquity>
    <gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416791"
      unitRef="Share">341224</gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416792"
      unitRef="USD">341</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416793"
      unitRef="USD">3155957</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416794"
      unitRef="USD">0</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416795"
      unitRef="USD">3156298</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416796"
      unitRef="Share">100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416797"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416798"
      unitRef="USD">1335</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416799"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416800"
      unitRef="USD">1335</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416802"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416803"
      unitRef="USD">18218</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416804"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416805"
      unitRef="USD">18218</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416807"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416808"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-07-01_2025-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416809"
      unitRef="USD">-3799240</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138416810"
      unitRef="USD">-3799240</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416811"
      unitRef="Share">1004247</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416812"
      unitRef="USD">1004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416813"
      unitRef="USD">168004988</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416814"
      unitRef="USD">-167238185</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416815"
      unitRef="USD">767807</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c138416817"
      unitRef="Share">29735</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416818"
      unitRef="USD">30</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416819"
      unitRef="USD">141104634</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416820"
      unitRef="USD">-133688280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c138416821"
      unitRef="USD">7416384</us-gaap:StockholdersEquity>
    <gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416822"
      unitRef="Share">6469</gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416823"
      unitRef="USD">6</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416824"
      unitRef="USD">6793193</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416825"
      unitRef="USD">0</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138416826"
      unitRef="USD">6793199</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416827"
      unitRef="Share">728</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416828"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416829"
      unitRef="USD">180719</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416830"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138416831"
      unitRef="USD">180720</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416832"
      unitRef="Share">1294</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <gnpx:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416833"
      unitRef="USD">1</gnpx:StockIssuedDuringPeriodValuesReverseStockSplits>
    <gnpx:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416834"
      unitRef="USD">-1</gnpx:StockIssuedDuringPeriodValuesReverseStockSplits>
    <gnpx:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416835"
      unitRef="USD">0</gnpx:StockIssuedDuringPeriodValuesReverseStockSplits>
    <gnpx:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138416836"
      unitRef="USD">0</gnpx:StockIssuedDuringPeriodValuesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416837"
      unitRef="Share">243</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416838"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416839"
      unitRef="USD">-1</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416840"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138416841"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416843"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416844"
      unitRef="USD">335246</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416845"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138416846"
      unitRef="USD">335246</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416848"
      unitRef="USD">-0</gnpx:DeemedDividendWarrantModification>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416849"
      unitRef="USD">277119</gnpx:DeemedDividendWarrantModification>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416850"
      unitRef="USD">-0</gnpx:DeemedDividendWarrantModification>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138416851"
      unitRef="USD">277119</gnpx:DeemedDividendWarrantModification>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416853"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416854"
      unitRef="USD">277119</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416855"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138416856"
      unitRef="USD">277119</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416858"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416859"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416860"
      unitRef="USD">-5968869</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138416861"
      unitRef="USD">-5968869</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c138416862"
      unitRef="Share">38469</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416863"
      unitRef="USD">39</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416864"
      unitRef="USD">148413790</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416865"
      unitRef="USD">-139657149</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c138416866"
      unitRef="USD">8756680</us-gaap:StockholdersEquity>
    <gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416867"
      unitRef="Share">12174</gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416868"
      unitRef="USD">12</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416869"
      unitRef="USD">20749</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416870"
      unitRef="USD">0</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138416871"
      unitRef="USD">20761</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416872"
      unitRef="Share">100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416873"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416874"
      unitRef="USD">14850</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416875"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138416876"
      unitRef="USD">14850</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416877"
      unitRef="Share">390</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416878"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416879"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416880"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138416881"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416883"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416884"
      unitRef="USD">2049104</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416885"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138416886"
      unitRef="USD">2049104</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416888"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416889"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416890"
      unitRef="USD">-6495846</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138416891"
      unitRef="USD">-6495846</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416892"
      unitRef="Share">51133</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416893"
      unitRef="USD">51</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416894"
      unitRef="USD">150498493</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416895"
      unitRef="USD">-146152995</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c138416896"
      unitRef="USD">4345549</us-gaap:StockholdersEquity>
    <gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416897"
      unitRef="Share">58570</gnpx:StockAndWarrantsIssuedDuringPeriodSharesNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416898"
      unitRef="USD">59</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416899"
      unitRef="USD">1215124</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416900"
      unitRef="USD">0</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416901"
      unitRef="USD">1215183</gnpx:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416902"
      unitRef="Share">100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416903"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416904"
      unitRef="USD">9650</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416905"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416906"
      unitRef="USD">9650</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416908"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416909"
      unitRef="USD">410576</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416910"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416911"
      unitRef="USD">410576</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416913"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416914"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-07-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416915"
      unitRef="USD">-4315987</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138416916"
      unitRef="USD">-4315987</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416917"
      unitRef="Share">109803</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c138416918"
      unitRef="USD">110</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c138416919"
      unitRef="USD">152133843</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c138416920"
      unitRef="USD">-150468982</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c138416921"
      unitRef="USD">1664971</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416927"
      unitRef="USD">-12438742</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416928"
      unitRef="USD">-16780702</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416930"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416931"
      unitRef="USD">6230</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-ExcludingElocPurchaseAgreementMember"
      decimals="INF"
      id="c138416932"
      unitRef="USD">659252</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-ExcludingElocPurchaseAgreementMember"
      decimals="INF"
      id="c138416933"
      unitRef="USD">3000146</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138416934"
      unitRef="USD">455549</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138416935"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416937"
      unitRef="USD">135978</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416938"
      unitRef="USD">-374916</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <gnpx:IncreaseDecreaseInResearchAndDevelopmentSupplies
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416939"
      unitRef="USD">-199446</gnpx:IncreaseDecreaseInResearchAndDevelopmentSupplies>
    <gnpx:IncreaseDecreaseInResearchAndDevelopmentSupplies
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416940"
      unitRef="USD">-358189</gnpx:IncreaseDecreaseInResearchAndDevelopmentSupplies>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416941"
      unitRef="USD">545150</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416942"
      unitRef="USD">-93488</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416943"
      unitRef="USD">-497615</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416944"
      unitRef="USD">-918427</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416945"
      unitRef="USD">-11212938</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416946"
      unitRef="USD">-14053136</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416948"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416949"
      unitRef="USD">1167</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416950"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416951"
      unitRef="USD">773478</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416952"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416953"
      unitRef="USD">774645</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416955"
      unitRef="USD">10714593</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416956"
      unitRef="USD">8029143</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416957"
      unitRef="USD">10714593</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416958"
      unitRef="USD">8029143</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416959"
      unitRef="USD">-498345</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416960"
      unitRef="USD">-5249348</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138416961"
      unitRef="USD">1601660</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c138416962"
      unitRef="USD">6737629</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138416963"
      unitRef="USD">1103315</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c138416964"
      unitRef="USD">1488281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138416966"
      unitRef="USD">-0</gnpx:DeemedDividendWarrantModification>
    <gnpx:DeemedDividendWarrantModification
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138416967"
      unitRef="USD">277119</gnpx:DeemedDividendWarrantModification>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072283">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Description of Business and Basis of Presentation&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Unless the context requires otherwise, references to &#x201c;Genprex,&#x201d; or the &#x201c;Company,&#x201d; in this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q refer to Genprex, Inc.&#160;Genprex, incorporated in Delaware in &lt;em style="font: inherit;"&gt; April 2008, &lt;/em&gt;is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. The Company&#x2019;s oncology platform utilizes its systemic, non-viral ONCOPREX&#xae; Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.&#160;The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.&#160;The Company&#x2019;s diabetes technology is designed to work in Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be distinct enough from beta cells to evade the body&#x2019;s immune system. In Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes, the Company&#x2019;s technology is believed to work by replenishing and rejuvenating exhausted beta cells&#160;that make insulin.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27.8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Oncology Platform&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Genprex&#x2019;s lead oncology drug candidate, REQORSA&#xae; gene therapy (generic name: &lt;i&gt;quaratusugene ozeplasmid&lt;/i&gt;), previously referred to as GPX-&lt;em style="font: inherit;"&gt;001,&lt;/em&gt; is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (&#x201c;NSCLC&#x201d;) and Small Cell Lung Cancer (&#x201c;SCLC&#x201d;). REQORSA has multimodal effects on cancer cells. It harms the metabolism of cancer cells, which leads to reduced cancer cell growth. It has a&#160;mechanism of action whereby it decreases tumor glucose metabolism, interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and increases the immune response against cancer cells. In preclinical studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies.&#160;The Company&#x2019;s strategy is to develop REQORSA in combination with currently approved therapies and the Company believes REQORSA&#x2019;s unique attributes position it to provide treatments that improve on these current therapies&#160;for patients with NSCLC, SCLC, and possibly other cancers.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The &lt;em style="font: inherit;"&gt;TUSC2&lt;/em&gt; gene, which is the key component of REQORSA and plays a vital role in cancer suppression and normal cell metabolism, is &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of a series of genes on the short arm of Chromosome &lt;em style="font: inherit;"&gt;3&lt;/em&gt; whose therapeutic use is covered by the Company&#x2019;s exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;).&#160;The Company believes that its ONCOPREX Delivery System allows for the delivery of a number of cancer-fighting tumor suppressor genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and the Company is&#160;in early stages of discovery programs to identify other cancer candidates. In &lt;em style="font: inherit;"&gt; August 2022, &lt;/em&gt;the Company entered into a&#160;sponsored research agreement with MD Anderson to support further preclinical studies of &lt;em style="font: inherit;"&gt;TUSC2&lt;/em&gt; and other tumor suppressor genes. Additionally, the Company is&#160;collaborating with MD Anderson to discover, develop and utilize biomarkers to select the patient population most likely to respond to REQORSA and enable decisions on progression of its drug candidates to the next phase of development. MD Anderson researchers currently are analyzing biomarkers that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;indicate a strong positive or negative response to REQORSA in lung cancer that could be used to enrich the Company&#x2019;s population of responders in its clinical trials.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Acclaim &#x2013; &lt;em style="font: inherit;"&gt;1:&lt;/em&gt; The Company currently is enrolling and treating patients in the Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; expansion portion of its Phase&#160;&lt;em style="font: inherit;"&gt;1/2&lt;/em&gt;&#160;Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;clinical trial.&#160;The Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;trial uses a combination of REQORSA and AstraZeneca&#x2019;s Tagrisso&#xae; (&lt;i&gt;osimertinib&lt;/i&gt;) in patients with late-stage NSCLC that has activating epidermal growth factor receptor (&#x201c;EGFR&#x201d;) mutations and progression on treatment with Tagrisso or Tagrisso-containing regimens. Following the &lt;em style="font: inherit;"&gt; May 2023 &lt;/em&gt;completion of the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; dose escalation portion of the study, the Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; Safety Review Committee (&#x201c;Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; SRC&#x201d;) approved advancement from the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; dose escalation portion to the Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; expansion portion of the study.&#160;Based on a review of safety data which showed &lt;em style="font: inherit;"&gt;no&lt;/em&gt; dose limiting toxicities (&#x201c;DLTs&#x201d;), the Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; SRC determined the recommended Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; dose (&lt;em style="font: inherit;"&gt;&#x201c;RP2D&#x201d;&lt;/em&gt;) of REQORSA to be &lt;em style="font: inherit;"&gt;0.12&lt;/em&gt; mg/kg. This was the highest dose level delivered in the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; portion of the study and is twice the highest dose level delivered in the Company&#x2019;s prior clinical trial combining REQORSA with Tarceva&#xae; (&lt;i&gt;erlotinib&lt;/i&gt;) for the treatment of late-stage lung cancer. There were &lt;em style="font: inherit;"&gt;three&lt;/em&gt; patients out of the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; originally enrolled in the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; dose escalation portion of the study who had prolonged progression-free survival&#160;(&#x201c;PFS&#x201d;). One patient&#160;attained a partial remission after the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; course of REQORSA and Tagrisso and has maintained this response through &lt;em style="font: inherit;"&gt;56&lt;/em&gt; courses of treatment (approximately &lt;em style="font: inherit;"&gt;39&lt;/em&gt; months) and continues to receive REQORSA and Tagrisso treatment to date. A &lt;em style="font: inherit;"&gt;second&lt;/em&gt; patient had&#160;stable disease without disease progression through &lt;em style="font: inherit;"&gt;32&lt;/em&gt; courses of treatment (approximately &lt;em style="font: inherit;"&gt;24&lt;/em&gt; months) but then had disease progression and REQORSA treatment was stopped. A &lt;em style="font: inherit;"&gt;third&lt;/em&gt; patient had stable disease without disease progression through &lt;em style="font: inherit;"&gt;14&lt;/em&gt; courses of treatment (approximately &lt;em style="font: inherit;"&gt;10&lt;/em&gt; months) before disease progression and is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer receiving treatment. Genprex opened the Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; expansion portion of the study and enrolled and dosed the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; patient in &lt;em style="font: inherit;"&gt; January 2024. &lt;/em&gt;The initial trial design of the Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; expansion portion of the study included &lt;em style="font: inherit;"&gt;two&lt;/em&gt; cohorts with half being patients who received only prior Tagrisso treatment and the other half being patients who received prior Tagrisso treatment and chemotherapy.&#160;However, as previously announced in &lt;em style="font: inherit;"&gt; August 2024, &lt;/em&gt;based on resource prioritization and to focus on the patients for whom REQORSA is most likely to show a benefit, the Company decided to limit its enrollment efforts moving forward to patients who received only prior Tagrisso treatment and cease enrollment of the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; cohort (patients who received prior Tagrisso treatment and chemotherapy). However, noting that &lt;em style="font: inherit;"&gt;two&lt;/em&gt; of the patients with prolonged PFS in the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; portion of the study had previously received both chemotherapy and Tagrisso, in &lt;em style="font: inherit;"&gt; February 2025, &lt;/em&gt;the Company amended the protocol to allow entry of patients progressing on Tagrisso or Tagrisso-containing regimens. The Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; expansion portion of the trial&#160;is now&#160;expected to enroll approximately &lt;em style="font: inherit;"&gt;33&lt;/em&gt;&#160;patients;&#160;all of whom have progressed on Tagrisso or Tagrisso-containing regimens. The Phase &lt;em style="font: inherit;"&gt;2b&lt;/em&gt; randomized portion of the study, in which patients progressing on prior Tagrisso treatment will be randomized &lt;em style="font: inherit;"&gt;1:1&lt;/em&gt; to either REQORSA and Tagrisso combination therapy or to platinum-based chemotherapy, remains unchanged.&#160;There will be an interim analysis following the treatment of &lt;em style="font: inherit;"&gt;19&lt;/em&gt; patients in the Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; portion of the Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; study. The Company expects to complete the enrollment of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;19&lt;/em&gt; patients for interim analysis in the Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; expansion portion of the study&#160;in the&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt; half&#160;of &lt;em style="font: inherit;"&gt;2026&lt;/em&gt;&#160;and expects the interim analysis in the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; half of &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Food and Drug Administration (&#x201c;FDA&#x201d;) has granted Fast Track Designation for the Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed on Tagrisso treatment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; expansion portion of the Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; study provides the Company the advantage of early insight into drug effectiveness in defined and distinct patient populations at the maximum tolerated dose or &lt;em style="font: inherit;"&gt;RP2D&lt;/em&gt; in order to better evaluate efficacy and increase the likelihood of a successful randomized Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; trial which will follow the expansion portion of the study.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: center; margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Acclaim &#x2013; &lt;em style="font: inherit;"&gt;2:&lt;/em&gt;&#160;The Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;trial involved a combination of REQORSA and Merck &amp;amp; Co.&#x2019;s Keytruda&#xae; (&lt;i&gt;pembrolizumab&lt;/i&gt;) in patients with late-stage NSCLC whose disease has progressed after treatment with Keytruda. As previously announced in &lt;em style="font: inherit;"&gt; August 2024, &lt;/em&gt;based on a number of factors, including enrollment challenges and delays due to competition for investigators and eligible patients with numerous other trials involving the same patient population, the Company decided to cease enrollment of new patients in the Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; trial to prioritize its resources and focus on the other &lt;em style="font: inherit;"&gt;two&lt;/em&gt; Acclaim trials in SCLC and NSCLC, respectively. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer any patients receiving study treatment in the Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; trial.&#160; Although the Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; study in patients progressing on Keytruda containing regimens has been closed due to, among other factors, slow enrollment, the Company continues to believe that this combination could be beneficial.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Acclaim &#x2013; &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&#160;The Company is&#160;currently enrolling and treating patients in the Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; expansion portion of its Phase&#160;&lt;em style="font: inherit;"&gt;1/2&lt;/em&gt;&#160;Acclaim-&lt;em style="font: inherit;"&gt;3&lt;/em&gt;&#160;clinical trial. The Acclaim-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; clinical trial uses a combination of REQORSA and Genentech, Inc.&#x2019;s Tecentriq&#xae; (&lt;i&gt;atezolizumab&lt;/i&gt;) as maintenance therapy for patients with extensive stage small cell lung cancer (&#x201c;ES-SCLC&#x201d;) who did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; develop&#160;tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Patients are treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.&#160;On &lt;em style="font: inherit;"&gt; December 16, 2024, &lt;/em&gt;the Company announced that it had completed the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; dose escalation portion of the Acclaim-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; clinical trial. Based on full safety data, which showed &lt;em style="font: inherit;"&gt;no&lt;/em&gt; DLTs, the Acclaim-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; Safety Review Committee determined that the &lt;em style="font: inherit;"&gt;RP2D&lt;/em&gt;&#160;of REQORSA will be &lt;em style="font: inherit;"&gt;0.12&lt;/em&gt; mg/kg, which was the highest dose level delivered in the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; portion of the trial, and approved the opening of the Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; expansion portion of the trial. The Company anticipates that the Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; expansion portion will enroll approximately &lt;em style="font: inherit;"&gt;50&lt;/em&gt; patients at approximately &lt;em style="font: inherit;"&gt;10&lt;/em&gt; to &lt;em style="font: inherit;"&gt;15&lt;/em&gt; U.S sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; portion is to determine the &lt;em style="font: inherit;"&gt;18&lt;/em&gt;-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. A Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; futility analysis will be performed after the &lt;em style="font: inherit;"&gt;25th&lt;/em&gt; patient enrolled and treated reaches &lt;em style="font: inherit;"&gt;18&lt;/em&gt; weeks of follow up. The Company expects to complete enrollment of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;25&lt;/em&gt; patients for interim analysis in the Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; expansion portion of the study&#160;in the&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt; half of &lt;em style="font: inherit;"&gt;2026&lt;/em&gt;&#160;and expects the interim analysis in the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; half of &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Acclaim-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; clinical trial has received FDA Fast Track Designation for this patient population&#160;and Acclaim-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; has also received an FDA Orphan Drug Designation.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Diabetes Gene Therapy&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In diabetes, Genprex has exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (&#x201c;University of Pittsburgh&#x201d; or &#x201c;UP&#x201d;) multiple technologies relating to the development of a gene therapy product for each of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes.&#160;The same general novel approach is used in each of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes whereby an adeno-associated virus vector containing the &lt;em style="font: inherit;"&gt;Pdx1&lt;/em&gt; and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. The Company&#x2019;s diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh. GPX-&lt;em style="font: inherit;"&gt;002&lt;/em&gt; is being developed using the same construct&#160;for the treatment of both&#160;Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes and&#160;Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes. GPX-&lt;em style="font: inherit;"&gt;002&lt;/em&gt; for Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be distinct enough from beta cells to evade the body&#x2019;s immune system. In a similar approach, GPX-&lt;em style="font: inherit;"&gt;002&lt;/em&gt; for Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes (formerly known as GPX-&lt;em style="font: inherit;"&gt;003&lt;/em&gt;), where autoimmunity is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; at play,&#160;is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin. The Company finalized the components of the diabetes construct to take forward for nonclinical studies and in &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the Company submitted a request to meet with the FDA to obtain their guidance on the nonclinical studies needed to file an Investigational New Drug (&#x201c;IND&#x201d;) application and initiate &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in-human studies. As a result of the FDA&#x2019;s response, Genprex decided to continue with its planned additional nonclinical studies before requesting regulatory guidance&#160;for the IND-enabling studies. The Company is&#160;currently working with the University of Pittsburgh on species analyses for the animal models as well as on other regulatory and clinical strategic planning, including the planned initiation of research in Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes animal models, following which the Company plans to submit a request to the FDA to meet regarding IND-enabling studies by the end of &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; In &lt;em style="font: inherit;"&gt; May 2025, &lt;/em&gt;following the recent completion of our&#160;&lt;em style="font: inherit;"&gt; August 2022&#160;&lt;/em&gt;sponsored research agreement with&#160;UP, Genprex entered into a new sponsored research agreement with UP to study Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes in animal models. The new sponsored research agreement&#160;also includes a revised research plan to encompass the Company&#x2019;s&#160;most recent technologies to which Genprex originally acquired exclusive rights from UP in &lt;em style="font: inherit;"&gt; July 2023 &lt;/em&gt;as amended and restated in the comprehensive New UP License Agreement in &lt;em style="font: inherit;"&gt; February 2025 (&lt;/em&gt;as defined and described below). These include a MafB promoter to drive expression of the &lt;em style="font: inherit;"&gt;Pdx1&lt;/em&gt; and MafA transcription factors that can potentially be used for both Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes.&#160;On&#160;&lt;em style="font: inherit;"&gt; February 17, 2025,&#160;&lt;/em&gt;Genprex and the University of Pittsburgh&#160;entered into an amended and restated Exclusive License Agreement (the &#x201c;New UP License Agreement&#x201d;), which updated and consolidated into a single agreement the Company&#x2019;s prior license agreements with UP. Pursuant to the New UP License Agreement, UP granted to Genprex a worldwide, exclusive license for certain patents and related technology, collectively referred to as the &#x201c;Licensed Technology,&#x201d; and a worldwide, non-exclusive license to use certain related know-how. The Licensed Technology covered by the New UP License Agreement is based on the same general gene therapy approach as covered under the Company&#x2019;s prior license agreements with UP (less the previously-licensed macrophage technology), whereby an adeno-associated virus vector containing the &lt;em style="font: inherit;"&gt;Pdx1&lt;/em&gt; and MafA genes is administered directly into the pancreatic duct. More specifically, the Licensed Technology covered by the New UP License Agreement is related to a gene therapy for both Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes using the genes of the &lt;em style="font: inherit;"&gt;Pdx1&lt;/em&gt; and MafA transcription factors controlled by insulin, glucagon and MafB promoters.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; February 2023, &lt;/em&gt;the Company&#x2019;s research collaborators at UP presented preclinical data in a non-human primate model of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes&#160;highlighting the therapeutic potential of GPX-&lt;em style="font: inherit;"&gt;002&lt;/em&gt; at the &lt;em style="font: inherit;"&gt;16th&lt;/em&gt; International Conference on Advanced Technologies &amp;amp; Treatments for Diabetes (&#x201c;ATTD &lt;em style="font: inherit;"&gt;2023&#x201d;&lt;/em&gt;) in Berlin, Germany. The statistically significant study results showed the treated animals had decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance compared to baseline.&#160;In &lt;em style="font: inherit;"&gt; April 2023, &lt;/em&gt;the Company hosted a Key Opinion Leader virtual event entitled &#x201c;Novel Gene Therapy to Treat Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; Diabetes,&#x201d; which discussed preclinical data reported at ATTD &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; supporting gene therapy to treat Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes. In &lt;em style="font: inherit;"&gt; June 2025, &lt;/em&gt;the Company&#x2019;s collaboration partners had &lt;em style="font: inherit;"&gt;two&lt;/em&gt; presentations at the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; American Diabetes Association (&#x201c;ADA&#x201d;) &lt;em style="font: inherit;"&gt;85th&lt;/em&gt; Scientific Sessions.&#160;Genprex&#x2019;s research collaborators from UP were invited to give an oral presentation highlighting their work in non-human primate models of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes.&#160; In addition, Genprex&#x2019;s contract development and manufacturing organization collaborators presented a poster on a&#160;non-viral lipid nanoparticle delivery system that would allow a patient to receive multiple treatments.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Formation of Wholly Owned Subsidiary&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 18, 2025, &lt;/em&gt;Genprex&#160;announced the formation of&#160;a wholly-owned subsidiary, Convergen Biotech, Inc. (&#x201c;Convergen&#x201d;). The Company intends to transfer the diabetes program into Convergen in an effort to&#160;focus development and commercialization efforts separately from the Company's oncology program.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Capital Requirements, Liquidity and Going Concern Considerations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America&#160;(&#x201c;US GAAP&#x201d;) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has sustained substantial losses from operations since inception and has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; current source of revenue. In addition, the Company has used, rather than provided, cash in its operations. Genprex expects to continue to incur significant expenditures to further clinical trials for the commercial development of its patents.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company recognizes that it must obtain additional capital resources to successfully commercialize its product candidates.&#160;To date, Genprex has received funding in the form of equity and debt, and the Company plans to seek additional funding in the future. However, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurances can be given that it will be successful in raising additional capital.&#160;If the Company is&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; able to timely and successfully raise additional capital, the timing of its clinical trials, financial condition and results of operations &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be materially and adversely affected. These unaudited condensed consolidated financial statements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Genprex believes that its current cash and cash equivalents&#160;will be sufficient&#160;to fund expenditure requirements for its necessary operations and expected clinical trial activities into &lt;em style="font: inherit;"&gt; March 2026. &lt;/em&gt;Genprex has based these estimates, however, on assumptions that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;prove to be wrong, and could spend available financial resources much faster than it currently expects. The Company will need to raise additional funds to continue funding its development and operations. The Company plans to secure such additional funding and is evaluating various strategies to obtain additional financing, although the Company can give &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that its plans or strategies will be effectively implemented in such a way that they will sufficiently alleviate or mitigate the conditions and events noted above.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company&#x2019;s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company&#x2019;s ability to continue as a going concern.&#160;These unaudited condensed consolidated financial statements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments that might be necessary if Genprex is&#160;unable to continue as a going concern.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&#160;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072284">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Genprex&#x2019;s&#160;unaudited&#160;condensed consolidated financial statements have been prepared in accordance with US&#160;GAAP&#160;and the requirements of the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that is normally required by US&#160;GAAP can be condensed or omitted. Accordingly, they do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes normally included in financial statements prepared in conformity with US&#160;GAAP. The &lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;balance sheet was derived from the &lt;em style="font: inherit;"&gt; December 31, 2024&#160;&lt;/em&gt;audited financial statements. Genprex&#x2019;s unaudited&#160;condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&#160;Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K, filed with the SEC on &lt;em style="font: inherit;"&gt; April 1, 2025&#160;(&lt;/em&gt;the &#x201c;Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K&#x201d;).&lt;/p&gt;
   &lt;p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;The accompanying condensed consolidated financial statements are unaudited and include all adjustments (consisting of normal recurring adjustments) that management considers necessary for a fair presentation of Genprex&#x2019;s condensed consolidated financial position and results of operations for the interim periods presented. The results of operations for the interim periods are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be expected for&#160;any other interim period or for&#160;the entire year.&lt;/p&gt;
   &lt;p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;A summary of Genprex&#x2019;s significant accounting policies consistently applied in the preparation of the accompanying unaudited condensed consolidated financial statements follows.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly-owned subsidiary,&#160;Convergen Biotech, Inc.,&#160;have been prepared in accordance with US GAAP for interim financial information and with the instructions to Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and Article &lt;em style="font: inherit;"&gt;10&lt;/em&gt; of Regulation S-&lt;em style="font: inherit;"&gt;X.&lt;/em&gt; All significant intercompany balances and transactions are eliminated in consolidation. As of&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, Convergen Biotech, Inc. has yet to initiate operating activity.&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Change in Accounting Principle&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, the Company changed an accounting principle related to accounting treatment of intellectual property expenditures. Previously, the Company capitalized certain intellectual property costs associated with the filing or maintenance of specific patents, including application costs, filing fees, and patent prosecution, in accordance with ASC &lt;em style="font: inherit;"&gt;350&lt;/em&gt;-&lt;em style="font: inherit;"&gt;30.&lt;/em&gt; The Company voluntarily changed this accounting principle to expense, rather than capitalize, these intellectual property costs on the basis that the new treatment is favorable.&#160;&lt;/p&gt;
   &lt;p style="text-align: justify; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/p&gt;&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 2, 2024, &lt;/em&gt;Genprex completed a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-40 reverse stock split (&lt;em style="font: inherit;"&gt;&#x201c;2024&lt;/em&gt; Reverse Split&#x201d;) of its issued and outstanding shares of common stock. The &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; Reverse Split did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; change the number of authorized shares of common stock or par value. All references in these unaudited condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; Reverse Split (see Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;&#x2013; Equity &#x2013; Reverse Stock Split).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 21, 2025, &lt;/em&gt;Genprex completed a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-50 reverse stock split (&lt;em style="font: inherit;"&gt;&#x201c;2025&lt;/em&gt;&#160;Reverse Split&#x201d;) of its issued and outstanding shares of common stock. The &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&#160;Reverse Split did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; change the number of authorized shares of common stock or par value. All references in these financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&#160;Reverse Split (See Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;&#x2013; Equity &#x2013; Reverse Stock Split).&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;The preparation of Genprex&#x2019;s unaudited condensed consolidated financial statements in conformity with US&#160;GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Genprex considers all highly liquid short-term investments with an initial maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents.&#160;Any amounts of cash in financial institutions which exceed Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits expose the Company to cash concentration risk. The Company has&#160;cash in a money market account&#160;and had $853,280&#160;and $1,351,625 in excess of FDIC insured limits of &lt;em style="font: inherit;"&gt;$250,000&lt;/em&gt; at &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, respectively.&#160;Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 45,313&#160;unexercised options granted by the Company&#x2019;s board of directors and unexercised warrants to purchase shares of common stock, and (ii) 1,360&#160;unvested restricted stock units granted by the Company&#x2019;s board of directors representing the right upon vesting to receive shares of common stock, in each case&#160;as of &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Segments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer and the Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is focused on pioneering the discovery and development of gene therapies for use in patient populations with unmet medical needs.&#160;See &#x201c;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt;&#160;&#x2013; Segment Reporting&#x201d; for additional disclosures related to segment reporting.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The carrying amounts reported in the condensed consolidated balance sheets for cash, money-market savings account, accounts receivable, and accounts payable&#160;approximate fair value because of the immediate or short-term maturity of these financial instruments.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Accounting Standards Codification ("ASC") &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC &lt;em style="font: inherit;"&gt;820&#x2019;s&lt;/em&gt; valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; classifies these inputs into the following hierarchy:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;1:&lt;/em&gt;&#160;Quoted prices for identical instruments in active markets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2:&lt;/em&gt; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&#160;Instruments with primarily unobservable value drivers.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Property&#160;and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from &lt;span style="-sec-ix-hidden:c138417188"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c138417189"&gt;five&lt;/span&gt; years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Research and Development&#160;Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies&#160;for current and future programs associated with the Company&#x2019;s preclinical and Phase &lt;em style="font: inherit;"&gt;1/2&lt;/em&gt; clinical trials. These expenditures are expensed in the period incurred and include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners,&#160;wages and associated employee benefits, facilities, and overhead costs.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Materials acquired to be used in clinical research,&#160;that have an alternative future use, are capitalized&#160;when the materials are acquired,&#160;and included in research and development supplies. These supplies are recognized as expense as they are consumed through use&#160;for testing or&#160;clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; alternative future use are expensed in the period acquired.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Research and development supplies&#160;purchased, valued at cost,&#160;and capitalized for future use were $1,847,412&#160;and $2,046,858&#160;at &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Intellectual property consists of&#160;legal and related costs associated with patents, trademarks,&#160;and other proprietary technology and rights developed, acquired, or licensed&#160;by Genprex. Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Accounting for Stock-Based Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date&#160;and recognizes the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. In evaluating the fair value and future benefits of its intangible assets, the Company performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. The Company recognizes an impairment loss if the carrying value of the asset exceeds the discounted expected future cash flows.&#160;During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, there were no deemed impairments of the Company&#x2019;s long-lived assets.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Derivative Liability&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt; &#x2013;&#160;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the condensed consolidated statement of operations within the other financing costs line item. The Company determined that certain features under the Equity Line of Credit (see Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;&#x2013; Equity&#160;&#x2013; Equity Line of Credit) qualified as an embedded derivative. The derivative liability is accounted for separately from the Equity Line of Credit&#160;Purchase Agreement and is accounted for at fair value. &lt;span style="-sec-ix-hidden:c138417199"&gt;$243,000&lt;/span&gt; has been recorded on the accompanying condensed consolidated balance sheet as of&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, related to this derivative liability.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Modification of Equity Classified Warrants&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; the effect of a modification shall be measured as the difference between the fair value of the modified warrant over and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for any incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt financing, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend.&#160;During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, there were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; modifications of equity classified warrants. During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&#160;months ended &lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt; the Company recognized a modification of an equity classified warrant as a deemed dividend.&lt;/p&gt;
   &lt;p style="text-align: justify; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Recent Accounting Developments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Accounting pronouncements issued but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; effective until after &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to have a significant effect on the Company&#x2019;s&#160;financial condition, results of operations, or cash flows.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; &#x201c;Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures,&#x201d; which modifies the rules on income tax disclosures to require disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The guidance is effective for annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2024, &lt;/em&gt;with early adoption permitted. The Company is currently evaluating the effect the amendments in ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; will have on its tax disclosures.&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424522">&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly-owned subsidiary,&#160;Convergen Biotech, Inc.,&#160;have been prepared in accordance with US GAAP for interim financial information and with the instructions to Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and Article &lt;em style="font: inherit;"&gt;10&lt;/em&gt; of Regulation S-&lt;em style="font: inherit;"&gt;X.&lt;/em&gt; All significant intercompany balances and transactions are eliminated in consolidation. As of&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, Convergen Biotech, Inc. has yet to initiate operating activity.&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <gnpx:ChangeInAccountingPrinciplePolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424523">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Change in Accounting Principle&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, the Company changed an accounting principle related to accounting treatment of intellectual property expenditures. Previously, the Company capitalized certain intellectual property costs associated with the filing or maintenance of specific patents, including application costs, filing fees, and patent prosecution, in accordance with ASC &lt;em style="font: inherit;"&gt;350&lt;/em&gt;-&lt;em style="font: inherit;"&gt;30.&lt;/em&gt; The Company voluntarily changed this accounting principle to expense, rather than capitalize, these intellectual property costs on the basis that the new treatment is favorable.&#160;&lt;/p&gt;
   &lt;p style="text-align: justify; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/p&gt;</gnpx:ChangeInAccountingPrinciplePolicyTextBlock>
    <gnpx:ReverseStockSplitPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424524">&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 2, 2024, &lt;/em&gt;Genprex completed a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-40 reverse stock split (&lt;em style="font: inherit;"&gt;&#x201c;2024&lt;/em&gt; Reverse Split&#x201d;) of its issued and outstanding shares of common stock. The &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; Reverse Split did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; change the number of authorized shares of common stock or par value. All references in these unaudited condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; Reverse Split (see Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;&#x2013; Equity &#x2013; Reverse Stock Split).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 21, 2025, &lt;/em&gt;Genprex completed a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-50 reverse stock split (&lt;em style="font: inherit;"&gt;&#x201c;2025&lt;/em&gt;&#160;Reverse Split&#x201d;) of its issued and outstanding shares of common stock. The &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&#160;Reverse Split did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; change the number of authorized shares of common stock or par value. All references in these financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&#160;Reverse Split (See Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;&#x2013; Equity &#x2013; Reverse Stock Split).&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;</gnpx:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-02-02_2024-02-02_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c138417152"
      unitRef="Pure">40</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2025-10-21_2025-10-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417167"
      unitRef="Pure">50</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:UseOfEstimates contextRef="d_2025-01-01_2025-09-30" id="c138424525">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;The preparation of Genprex&#x2019;s unaudited condensed consolidated financial statements in conformity with US&#160;GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424526">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Genprex considers all highly liquid short-term investments with an initial maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents.&#160;Any amounts of cash in financial institutions which exceed Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits expose the Company to cash concentration risk. The Company has&#160;cash in a money market account&#160;and had $853,280&#160;and $1,351,625 in excess of FDIC insured limits of &lt;em style="font: inherit;"&gt;$250,000&lt;/em&gt; at &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, respectively.&#160;Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417174"
      unitRef="USD">853280</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417175"
      unitRef="USD">1351625</us-gaap:CashUninsuredAmount>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424527">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 45,313&#160;unexercised options granted by the Company&#x2019;s board of directors and unexercised warrants to purchase shares of common stock, and (ii) 1,360&#160;unvested restricted stock units granted by the Company&#x2019;s board of directors representing the right upon vesting to receive shares of common stock, in each case&#160;as of &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c138417177"
      unitRef="Share">45313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417178"
      unitRef="Share">1360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424528">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Segments&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer and the Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is focused on pioneering the discovery and development of gene therapies for use in patient populations with unmet medical needs.&#160;See &#x201c;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt;&#160;&#x2013; Segment Reporting&#x201d; for additional disclosures related to segment reporting.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2025-01-01_2025-09-30" id="c138424529">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The carrying amounts reported in the condensed consolidated balance sheets for cash, money-market savings account, accounts receivable, and accounts payable&#160;approximate fair value because of the immediate or short-term maturity of these financial instruments.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Accounting Standards Codification ("ASC") &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC &lt;em style="font: inherit;"&gt;820&#x2019;s&lt;/em&gt; valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; classifies these inputs into the following hierarchy:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;1:&lt;/em&gt;&#160;Quoted prices for identical instruments in active markets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2:&lt;/em&gt; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&#160;Instruments with primarily unobservable value drivers.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424530">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Property&#160;and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from &lt;span style="-sec-ix-hidden:c138417188"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c138417189"&gt;five&lt;/span&gt; years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2025-01-01_2025-09-30" id="c138424531">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Research and Development&#160;Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies&#160;for current and future programs associated with the Company&#x2019;s preclinical and Phase &lt;em style="font: inherit;"&gt;1/2&lt;/em&gt; clinical trials. These expenditures are expensed in the period incurred and include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners,&#160;wages and associated employee benefits, facilities, and overhead costs.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Materials acquired to be used in clinical research,&#160;that have an alternative future use, are capitalized&#160;when the materials are acquired,&#160;and included in research and development supplies. These supplies are recognized as expense as they are consumed through use&#160;for testing or&#160;clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; alternative future use are expensed in the period acquired.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Research and development supplies&#160;purchased, valued at cost,&#160;and capitalized for future use were $1,847,412&#160;and $2,046,858&#160;at &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <gnpx:ResearchAndDevelopmentAssetsCurrent
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417192"
      unitRef="USD">1847412</gnpx:ResearchAndDevelopmentAssetsCurrent>
    <gnpx:ResearchAndDevelopmentAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417193"
      unitRef="USD">2046858</gnpx:ResearchAndDevelopmentAssetsCurrent>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2025-01-01_2025-09-30" id="c138424532">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Intellectual property consists of&#160;legal and related costs associated with patents, trademarks,&#160;and other proprietary technology and rights developed, acquired, or licensed&#160;by Genprex. Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2025-01-01_2025-09-30" id="c138424533">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Accounting for Stock-Based Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date&#160;and recognizes the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424534">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. In evaluating the fair value and future benefits of its intangible assets, the Company performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. The Company recognizes an impairment loss if the carrying value of the asset exceeds the discounted expected future cash flows.&#160;During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, there were no deemed impairments of the Company&#x2019;s long-lived assets.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="d_2025-01-01_2025-09-30"
      decimals="-3"
      id="c138417196"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DerivativesPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424535">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Derivative Liability&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt; &#x2013;&#160;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;. An embedded derivative that requires separation is accounted for as a separate asset or liability from the host agreement. The derivative asset or liability is accounted for at fair value, with changes in fair value recognized in the condensed consolidated statement of operations within the other financing costs line item. The Company determined that certain features under the Equity Line of Credit (see Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;&#x2013; Equity&#160;&#x2013; Equity Line of Credit) qualified as an embedded derivative. The derivative liability is accounted for separately from the Equity Line of Credit&#160;Purchase Agreement and is accounted for at fair value. &lt;span style="-sec-ix-hidden:c138417199"&gt;$243,000&lt;/span&gt; has been recorded on the accompanying condensed consolidated balance sheet as of&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, related to this derivative liability.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <gnpx:WarrantModificationPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424536">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Modification of Equity Classified Warrants&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; the effect of a modification shall be measured as the difference between the fair value of the modified warrant over and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for any incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt financing, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend.&#160;During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, there were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; modifications of equity classified warrants. During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&#160;months ended &lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt; the Company recognized a modification of an equity classified warrant as a deemed dividend.&lt;/p&gt;
   &lt;p style="text-align: justify; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;/p&gt;</gnpx:WarrantModificationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-09-30" id="c138424537">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Recent Accounting Developments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Accounting pronouncements issued but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; effective until after &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to have a significant effect on the Company&#x2019;s&#160;financial condition, results of operations, or cash flows.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; &#x201c;Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures,&#x201d; which modifies the rules on income tax disclosures to require disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The guidance is effective for annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2024, &lt;/em&gt;with early adoption permitted. The Company is currently evaluating the effect the amendments in ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; will have on its tax disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072285">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; - Intellectual Property&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, Genprex owned or had exclusive license agreements on 15&#160;granted patents and 26&#160;pending patent applications&#160;worldwide for technologies developed in-house or by researchers at the National Cancer Institute, New York University, The University of Texas MD Anderson Cancer Center,&#160;the University of Texas Southwestern Medical Center, the University of Texas Health Sciences Center at Houston, the University of Michigan, and the University of Pittsburgh.&#160;These patents comprise various therapeutic, diagnostic, technical and processing claims and costs are expensed as incurred.&#160;These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;University of Pittsburgh&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On&#160;&lt;em style="font: inherit;"&gt; February 17, 2025,&#160;&lt;/em&gt;Genprex and the University of Pittsburgh entered into an amended and restated Exclusive License Agreement (the &#x201c;New UP License Agreement&#x201d;)&#160;to update&#160;and consolidate,&#160;into a single agreement, prior license agreements and licensed technologies&#160;covered by the prior University of Pittsburgh agreements&#160;related to a gene therapy for both Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes using the genes of the &lt;em style="font: inherit;"&gt;Pdx1&lt;/em&gt; and MafA transcription factors controlled by insulin, glucagon and MafB promoters. As of &lt;em style="font: inherit;"&gt; February 17, 2025, &lt;/em&gt;the New UP License Agreement effectuates the termination of, and amends, restates, replaces and supersedes in their entirety, the prior license agreements between Genprex and the University of Pittsburgh which were effective as of &lt;em style="font: inherit;"&gt; February 10, 2020 (&lt;/em&gt;as amended &lt;em style="font: inherit;"&gt; August 17, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; November 3, 2022), &lt;/em&gt;&lt;em style="font: inherit;"&gt; December 29, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; July 14, 2023. &lt;/em&gt;Genprex also terminated, effective &lt;em style="font: inherit;"&gt; February 17, 2025, &lt;/em&gt;a prior agreement with UP related to a license for macrophage technology dated&#160;&lt;em style="font: inherit;"&gt; November 22, 2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;The University of Texas MD Anderson Cancer Center&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; May 4, 2020, &lt;/em&gt;Genprex entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson relating&#160;to a portfolio of patent applications and related technology for the treatment of cancer using the Company&#x2019;s lead drug candidate and immunotherapies.&#160;&#160;See &#x201c;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; - Commitments and Contingencies - Commitments - MD Anderson Cancer Center&#x201d; for information on additional agreements involving MD Anderson licensed rights and technologies.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;University of Michigan&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; November 11, 2024, &lt;/em&gt;Genprex and the Regents of the University of Michigan (&#x201c;UM&#x201d; or the &#x201c;University of Michigan&#x201d;) entered into a Patent License Agreement (&#x201c;UM License Agreement&#x201d;), which granted Genprex a worldwide, exclusive license to the University of Michigan&#x2019;s patent rights in a co-owned patent application relating to the use of REQORSA in combination with ALK-inhibitors for the treatment of ALK-&lt;em style="font: inherit;"&gt;EML4&lt;/em&gt; positive translocated lung cancer.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;New York University&#160;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; April 25, 2025, &lt;/em&gt;the Company and New York University (&#x201c;NYU&#x201d;) entered into a License Agreement (the &#x201c;NYU License Agreement&#x201d;), which granted Genprex patent exclusivity and commercial rights worldwide relating to Genprex&#x2019;s lead drug candidate REQORSA for the potential treatment of mesothelioma.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;University of Texas Health Sciences Center at Houston&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; May 2, 2025, &lt;/em&gt;the Company and the Board of Regents of The University of Texas System on behalf of The University of Texas Health Sciences Center at Houston (&#x201c;UTHealth Houston&#x201d; or &#x201c;UTH&#x201d;) entered into a Patent and Technology License Agreement (the &#x201c;UTH License Agreement&#x201d;), which granted Genprex exclusivity and commercial rights worldwide relating to Genprex&#x2019;s lead drug candidate REQORSA for the potential treatment of glioblastoma.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;GENPREX, INC.&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt; SEPTEMBER 30, 2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IntangibleAssetsDisclosureTextBlock>
    <gnpx:NumberOfGrantedPatents
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138417226"
      unitRef="Pure">15</gnpx:NumberOfGrantedPatents>
    <gnpx:NumberOfPendingPatentApplications
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138417227"
      unitRef="Pure">26</gnpx:NumberOfPendingPatentApplications>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072286">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;- Equity&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 2, 2024, &lt;/em&gt;Genprex completed a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-40 Reverse Split of its issued and outstanding shares of common stock. The &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; Reverse Split did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; change the number of authorized shares of common stock or the par value. All references in these unaudited condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; Reverse Split.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 21, 2025, &lt;/em&gt;Genprex completed a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-50 Reverse Split of its issued and outstanding shares of common stock. The Reverse Split did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; change the number of authorized shares of common stock or the par value. All references in these unaudited condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the Reverse Split.&#160;See &#x201c;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;&#160;- Subsequent Events - &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; Reverse Stock Split&#x201d; for a description of the Reverse Split.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Registered Direct Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 21, 2024,&#160;&lt;/em&gt;the Company completed a registered direct offering priced at the market under Nasdaq rules, in which the Company sold to an institutional investor an aggregate of (i)&#160;&#160;3,300&#160;shares of common stock, (ii) pre-funded warrants (the&#160;&lt;em style="font: inherit;"&gt; &#x201c;March 2024 &lt;/em&gt;Pre-Funded Warrants&#x201d;) exercisable for up to an aggregate of&#160;27,543 shares of common stock, and (iii) warrants (the&#160;&lt;em style="font: inherit;"&gt; &#x201c;March 2024 &lt;/em&gt;Common Warrants&#x201d;) exercisable for up to an aggregate of&#160;30,843&#160;shares of common stock.&#160;The offering price for each share of common stock and accompanying &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Common Warrant was $210.75,&#160;and the offering price for each &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Pre-Funded Warrant and accompanying &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Common Warrant was $210.75.&#160;The &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Pre-Funded Warrants were&#160;exercisable immediately upon issuance at an exercise price of $0.005&#160;per share and expired when exercised in full.&#160;The &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Common Warrants are exercisable immediately upon issuance at an exercise price of $204.50 per share and will expire in &lt;span style="-sec-ix-hidden:c138417252"&gt;five&lt;/span&gt;&#160;years from the date of issuance. The Company received net proceeds of approximately $5.8 million after commissions and&#160;expenses, excluding any proceeds received from any exercise of the &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Common Warrants. In connection with the offering, the Company also amended certain existing warrants to purchase up to an aggregate of 3,886 shares of common stock that were previously issued to investors in &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; July 2023, &lt;/em&gt;with exercise prices of $2,200.00 and $1,770.00&#160;per share and expiration dates of &lt;em style="font: inherit;"&gt; March 1, 2028 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; July 21, 2028 &lt;/em&gt;for $6.25 per amended warrant, such that the amended warrants have a reduced exercise price of $204.50 per share and an expiration date of &lt;span style="-sec-ix-hidden:c138417259"&gt;five&lt;/span&gt; years from the closing of the &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;offering. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;,&#160;all of the&#160;27,543 &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Pre-Funded Warrants had been exercised for shares of common stock.&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;At-The-Market Offering&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;On &lt;em style="font: inherit;"&gt; December 13, 2023, &lt;/em&gt;Genprex entered into an At The Market (&#x201c;ATM&#x201d;) Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC, serving as agent (the &#x201c;Agent&#x201d;) with respect to an at-the-market offering program (the &lt;em style="font: inherit;"&gt;&#x201c;2023&lt;/em&gt; ATM Facility&#x201d;) under which the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell through the Agent, from time to time at its&#160;sole discretion, up to such number or dollar amount of shares of its common stock (the &#x201c;Shares&#x201d;) as registered on the prospectus supplement covering the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; ATM Facility offering, as &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be amended or supplemented from time to time. Any Shares offered and sold pursuant to the Sales Agreement will be issued pursuant to the Company&#x2019;s currently effective shelf Registration Statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; (File &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;333&lt;/em&gt;-&lt;em style="font: inherit;"&gt;271386&lt;/em&gt;) filed with the SEC on &lt;em style="font: inherit;"&gt; April 21, 2023, &lt;/em&gt;which was declared effective on &lt;em style="font: inherit;"&gt; June 9, 2023. &lt;/em&gt;The Company has agreed to pay the Agent a commission equal to &lt;em style="font: inherit;"&gt;three&lt;/em&gt; percent (3%) of the gross sales proceeds of any Shares sold through the Agent under the Sales Agreement, and also have provided the Agent with customary indemnification and contribution rights. There were no sales of common stock pursuant to the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; ATM Facility during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025. &lt;/em&gt;During the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company sold&#160;&lt;/span&gt;338,811&lt;span style="background-color:#ffffff;"&gt; shares of common stock for aggregate net proceeds of&#160;&lt;/span&gt;$6,895,947&lt;span style="background-color:#ffffff;"&gt; under the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;ATM Facility. See&#160;&lt;/span&gt;&#x201c;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;&#160;- Subsequent Events - At-The-Market Offering&#x201d; for a description of the prospectus supplement filed by the Company on &lt;em style="font: inherit;"&gt; November 10, 2025 &lt;/em&gt;and the Company&lt;span style="background-color:#ffffff"&gt;&#x2019;&lt;/span&gt;s usage of the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; ATM Facility subsequent to &lt;em style="font: inherit;"&gt; September 30, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Equity Line of Credit&#160;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;On &lt;em style="font: inherit;"&gt; June 11, 2025, &lt;/em&gt;Genprex entered into an equity line of credit (&#x201c;ELOC&#x201d;) purchase agreement (the &#x201c;Purchase Agreement&#x201d;)&#160;with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;), pursuant to which Lincoln Park committed to purchase up to $12.5 million in shares of the Company&#x2019;s common stock (subject to certain conditions and limitations contained in the Purchase Agreement) from time to time at the Company&#x2019;s sole discretion over the &lt;em style="font: inherit;"&gt;24&lt;/em&gt;-month term of the Purchase Agreement&#160;(the &lt;em style="font: inherit;"&gt;&#x201c;2025&lt;/em&gt; ELOC Facility&#x201d;).&#160;Sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and the Company&#x2019;s determination as to the appropriate sources of funding for its operations.&#160;Due to certain pricing and settlement provisions, the Purchase Agreement qualifies as a standby purchase equity agreement and includes an embedded put option and an embedded forward contract. Genprex will account for the Purchase Agreement as a derivative measured at fair value, with changes in fair value recognized in the condensed&#160;consolidated statement of operations. &lt;/span&gt;The put option derivative liability is accounted for on a fair value basis under the provisions of ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt; &#x2013;&#160;Derivatives and Hedging.&#160;The derivative associated with the Purchase Agreement was deemed de minimus at inception until&#160;the Company obtained&#160;stockholder approval to issue shares of common stock to Lincoln Park under the Purchase Agreement&#160;in excess of the Exchange Cap. The fair value of the ELOC Purchase Agreement contemplated future purchase decisions based on economic considerations and relevant stock issuance rules and limitations and has been determined using a Monte Carlo simulation. The fair value of the ELOC derivative liability was $243,000 at&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The following table provides the carrying value and fair value of the ELOC derivative liability of the Company measured at fair value on a recurring basis as of &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 17.5%; margin-left: 17.5%; width: 65%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading GFJY4-DHU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DJN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurement at September 30, 2025&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DHU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DJN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Carrying Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 36%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Derivative liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;243,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;243,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Totals liabilities measured and recorded at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;243,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;243,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The following table provides quantitative information regarding fair value measurements inputs used with respect to the ELOC derivative liability, as of their respective measurement dates:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 27.5%; margin-left: 27.5%; width: 45%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading GFJY4-DHU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;September 30, 2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closing stock price:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;180.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years):&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.70&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;span style="background-color:#ffffff;"&gt;The Company expenses the difference between the discounted purchase price of the settled forward and the fair value of the shares on the date of settlement as a non-cash financing cost.&#160;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#160;sold&#160;341,224&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock to Lincoln Park as purchase shares for aggregate net proceeds of&#160;$2,943,745 &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;under the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; ELOC&#160;Facility.&#160;During the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company (i) issued&#160;23,737&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock to Lincoln Park with a value of&#160;&lt;/span&gt;$365,550&lt;span style="background-color:#ffffff;"&gt;&#160;as commitment shares pursuant to the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; ELOC Facility, which was expensed as incurred,&#160;and (ii) sold&#160;422,380&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock to Lincoln Park as purchase shares for aggregate net proceeds of&#160;&#160;$3,818,631&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;under the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; ELOC&#160;Facility.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;See &#x201c;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;&#160;&#x2013; Subsequent Events &#x2013; Share Issuances&#x201d; for a description of the Company&#x2019;s usage of the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; ELOC Facility subsequent to&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Stock Issuances&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company issued (i)&#160;&lt;/span&gt;100&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock for services provided to the Company valued at&#160;$1,335&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;to the Chairman of its Scientific Advisory Board, and (ii)&#160;341,224&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock sold to Lincoln Park as purchase shares for aggregate net proceeds of&#160;$2,943,745&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;under the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; ELOC&#160;Facility.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company issued (i)&#160;300&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock for services provided to the Company valued at&#160;$6,990&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;to the Chairman of its Scientific Advisory Board, (ii)&#160;&lt;/span&gt;1,785&lt;span style="background-color:#ffffff;"&gt; shares of common stock upon the vesting of restricted stock units (&#x201c;RSUs&#x201d;) valued at&#160;&lt;/span&gt;$21,922&lt;span style="background-color:#ffffff;"&gt; to Company executives, employees, and non-employee service providers,&#160;(iii)&#160;338,811&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock sold for aggregate net proceeds of&#160;$6,895,947&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;under the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;ATM Facility, (iv)&#160;&lt;/span&gt;23,737&lt;span style="background-color:#ffffff;"&gt; shares of common stock issued to Lincoln Park as commitment shares pursuant to the Company&#x2019;s &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; ELOC Facility, and (v)&#160;422,380&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock sold to Lincoln Park as purchase shares for aggregate net proceeds of&#160;&lt;/span&gt;$3,818,631&lt;span style="background-color:#ffffff;"&gt;&#160;under the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; ELOC&#160;Facility&#160;(inclusive of the shares issued during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, as described in the immediately preceding sentence).&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company issued (i)&#160;100&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock for services provided to the Company valued at&#160;&lt;/span&gt;$9,650&lt;span style="background-color:#ffffff;"&gt; to the Chairman of its Scientific Advisory Board,&#160;(ii)&#160;&lt;/span&gt;15,580&lt;span style="background-color:#ffffff;"&gt; shares of common stock&#160;upon the exercise of pre-funded warrants at a nominal exercise price associated with the Company&#x2019;s &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;offering (the remaining balance of the purchase price of each share of common stock associated with each pre-funded warrant having been previously paid as the investor&#x2019;s subscription price for the pre-funded warrants at the closing of such offering), and (iii)&#160;&lt;/span&gt;42,990&lt;span style="background-color:#ffffff;"&gt; shares of common stock sold for aggregate net proceeds of&#160;$1,215,105&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; ATM Facility.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company issued (i)&#160;203 &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock for services provided to the Company valued at&#160;$25,904&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;to the Chairman of its Scientific Advisory Board, (ii)&#160;&lt;/span&gt;725&lt;span style="background-color:#ffffff;"&gt; shares of common stock to service providers of the Company valued at &lt;/span&gt;$179,550&lt;span style="background-color:#ffffff;"&gt;,&#160;(iii)&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;633&#160;shares of common stock upon the vesting of restricted stock units (&#x201c;RSUs&#x201d;) valued at&#160;$96,524&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;to Company executives and employees, non-employee directors, and former Company executives (Mr. Varner and Ms. Vaczy) pursuant to the terms of employment and/or separation agreements, (iv)&#160;&lt;/span&gt;1,294&lt;span style="background-color:#ffffff;"&gt; shares of common stock due to adjustments related to the Company&#x2019;s Reverse Split, (v) &lt;/span&gt;46,370&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock sold&#160;for aggregate net proceeds of &lt;/span&gt;$2,117,752&lt;span style="background-color:#ffffff;"&gt;&#160;under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; ATM Facility, as described above, (vi)&#160;3,300&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock sold for aggregate net proceeds of&#160;approximately $5.8 million associated with the&#160;Company&#x2019;s &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;offering, as described above, and (vii)&#160;&lt;/span&gt;27,543&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock&#160;upon the exercise of pre-funded warrants at a nominal exercise price associated with the Company&#x2019;s &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;offering&#160;(the remaining balance of the purchase price of each share of common stock associated with each pre-funded warrant having been previously paid as the investor&#x2019;s subscription price for the pre-funded warrants at the closing of such offering) (inclusive of the shares issued during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, as described in the immediately preceding sentence).&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Genprex is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, &lt;span style="-sec-ix-hidden:c138417346"&gt;&lt;span style="-sec-ix-hidden:c138417347"&gt;none&lt;/span&gt;&lt;/span&gt; of which are&#160;outstanding as of&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Genprex is&#160;authorized to issue 200,000,000 shares of common stock with a par value of $0.001 per share, all of which are voting common stock. There were&#160;1,004,247 and&#160;217,234 shares of its common stock outstanding as of&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Common Stock Purchase Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;Common stock purchase warrant activity for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively, is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; margin-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; margin-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; margin-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; margin-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at January 1,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39,633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;503.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,052&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,054.81&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrants issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;64,124&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;118.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at March 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;39,633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;503.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;67,176&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;297.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Outstanding at June 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;39,633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;503.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;55,214&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;361.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;15,580&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants cancelled or expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,620.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at September 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,608&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;499.26&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,634&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;503.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;months&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;the Company (i) did &lt;span style="-sec-ix-hidden:c138417360"&gt;&lt;span style="-sec-ix-hidden:c138417361"&gt;not&lt;/span&gt;&lt;/span&gt; issue any warrants, and&#160;(ii) canceled warrants to purchase up to&#160;25&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock at a weighted average exercise price of&#160;&lt;/span&gt;$7,620.00&lt;span style="background-color:#ffffff;"&gt;. T&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;he Company did &lt;span style="-sec-ix-hidden:c138417365"&gt;&lt;span style="-sec-ix-hidden:c138417366"&gt;not&lt;/span&gt;&lt;/span&gt; record any share-based compensation related to warrants&#160;during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; or &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months&#160;ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;.&#160;The Company expects to record approximately&#160;$0.3&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;million of share-based compensation based on performance-based vesting in the future&#160;with respect to its warrants outstanding as of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;.&#160;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect&#160;to record share-based compensation for time-based vesting through the end of the fiscal year &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&#160;and expects to record approximately&#160;$0.3&#160;million of share-based compensation based on performance-based vesting in the future&#160;with respect to its warrants outstanding as of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;months&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;the Company (i) did &lt;span style="-sec-ix-hidden:c138417377"&gt;not&lt;/span&gt; issue any warrants, and&#160;(ii) issued&#160;15,580&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock associated with the partial exercise of &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Pre-Funded Warrants.&#160;During the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, and in connection with the&#160;registered direct offering, with an institutional investor,&#160;completed on &lt;em style="font: inherit;"&gt; March&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;21,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; Genprex (i) issued pre-funded warrants to purchase up to an aggregate of&#160;&lt;/span&gt;27,543&lt;span style="background-color:#ffffff;"&gt; shares of common stock at a nominal exercise price of $0.005 per share (such exercise price representing&#160;the remaining balance of the purchase price of each share of common stock associated with each pre-funded warrant net of the portion of the subscription price therefor paid at closing), (ii) issued warrants to purchase up to&#160;&lt;/span&gt;30,843&lt;span style="background-color:#ffffff;"&gt; shares of common stock, at&#160;an exercise price of $204.50 per share, (iii) issued warrants to purchase up to 1,851&#160;shares of common stock to H.C. Wainwright &amp;amp; Co., LLC or its designees (&#x201c;Placement Agent&#x201d;), at&#160;an exercise price of $260.44 per share, (iv) amended existing warrants to purchase up to an aggregate of 3,885 shares of common stock that were previously issued to the same institutional investor&#160;in &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; July 2023, &lt;/em&gt;such that the amended warrants have a reduced exercise price of $204.50 per share and an expiration date of &lt;span style="-sec-ix-hidden:c138417390"&gt;five&lt;/span&gt; years from the closing of the &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;offering, and (v)&#160;issued&#160;11,963 shares of common stock associated with the partial exercise of &lt;em style="font: inherit;"&gt; March 2024 &lt;/em&gt;Pre-Funded Warrants (inclusive of the shares issued during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;as described in the immediately preceding sentence).&#160;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months&#160;ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, Genprex recorded share-based compensation of $2,280 and $18,039, respectively,&#160;associated with the vesting and issuance of warrants.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company had&#160;outstanding warrants to purchase&#160;&lt;/span&gt;39,608&lt;span style="background-color:#ffffff;"&gt; shares of common stock at a weighted average exercise price of&#160;&lt;/span&gt;$499.26&lt;span style="background-color:#ffffff;"&gt; that have been issued to various consultants, investors, and placement agents.&#160;The&#160;warrants are fully vested, are exercisable for a period of up to &lt;span style="-sec-ix-hidden:c138417399"&gt;five&lt;/span&gt;&#160;years from the date of issuance, enable the holders to purchase shares of the Company&#x2019;s common stock at exercise prices ranging from&#160;$204.50&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;to&#160;$14,440.00&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;per share&#160;and have per-share fair values ranging from&#160;$60.67&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;to&#160;$9,250.20&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;, based on Black-Scholes-Merton pricing models. The following assumptions were used in calculation of fair market value of warrants granted via Black-Scholes-Merton pricing models for the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 40%; margin-left: 0pt; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Nine Months Ended September 30, 2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years):&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;5.0&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate:&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;4.52%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility:&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;87.49%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield:&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;0%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The Company&#x2019;s board of directors and stockholders have&#160;approved and adopted the Genprex &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan (&lt;em style="font: inherit;"&gt;&#x201c;2018&lt;/em&gt; Plan&#x201d;), which became effective on the completion of the Company&#x2019;s IPO on &lt;em style="font: inherit;"&gt; April 3, 2018.&#160;&lt;/em&gt;The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan provides for the grant of incentive stock options that are intended to qualify under Section &lt;em style="font: inherit;"&gt;422&lt;/em&gt; of the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; as amended (&#x201c;ISOs&#x201d;), nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance-based stock awards and performance-based cash awards. ISOs &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted only to employees. All other awards &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted to employees, including officers, and to the Company&#x2019;s non-employee directors and consultants.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;A total&lt;span style="background-color:#ffffff;"&gt; of &lt;/span&gt;2,080&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock were initially available under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, plus a number of shares of common stock (&lt;em style="font: inherit;"&gt;not&lt;/em&gt; to exceed &lt;/span&gt;1,314&lt;span style="background-color:#ffffff;"&gt;&#160;shares) su&lt;/span&gt;bject to outstanding awards under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2009&lt;/em&gt; Equity Incentive Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2009&lt;/em&gt; Plan&#x201d;) as of the IPO that expire, are forfeited or otherwise terminate or that are used to cover the exercise price or applicable tax withholdings. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; further grants will be made under the &lt;em style="font: inherit;"&gt;2009&lt;/em&gt; Plan. In addition, the number of shares of common stock reserved for issuance under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan automatically increases on &lt;em style="font: inherit;"&gt; January 1 &lt;/em&gt;of each year, since&#160;&lt;em style="font: inherit;"&gt; January 1, 2019, &lt;/em&gt;by 5% of the total number of shares of the Company&#x2019;s common stock outstanding on &lt;em style="font: inherit;"&gt; December 31 &lt;/em&gt;of the preceding calendar year, or a lesser number of shares determined by the Company&#x2019;s board of directors&#160;or a committee of the board of directors appointed to administer the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; August 15, 2025 &lt;/em&gt;at the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; Annual Meeting of Stockholders, the Company&#x2019;s stockholders approved the Company&#x2019;s amended and restated &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2018&lt;/em&gt; Amended Plan&#x201d;).&#160;The principal changes to the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan implemented by the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Amended&#160;Plan include amendments to (i) increase the number of shares of the Company&#x2019;s common stock authorized for issuance under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan by an additiona&lt;span style="background-color:#ffffff;"&gt;l &lt;/span&gt;130,000&lt;span style="background-color:#ffffff;"&gt;&#160;shares &lt;/span&gt;(subject to adjustment for stock splits, stock dividends and similar events),&#160;(ii) extend the term of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan to &lt;em style="font: inherit;"&gt; June 30, 2035 (&lt;/em&gt;the &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-year anniversary of the Board&#x2019;s adoption of the Amended Equity Plan) and (iii) remove provisions of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan that had been included to comply with the exception for the deductibility of &#x201c;performance-based compensation&#x201d; under Section &lt;em style="font: inherit;"&gt;162&lt;/em&gt;(m) of the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; as amended, which was repealed by the Tax Cuts and Jobs Act of &lt;em style="font: inherit;"&gt;2017.&lt;/em&gt; The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Amended Plan became effective upon its approval by the Company&#x2019;s stockholders at the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; Annual Meeting.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On&#160;&lt;em style="font: inherit;"&gt; January 1, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; the number of shares of common stock reserved for issuance under the&#160;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt;&#160;Plan&#160;was increased by an aggregate of&#160;1,486 and&#160;10,861 shares, respectively. As of &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, a total of&#160;144,588&#160;shares of common stock remain&#160;available for issuance under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Amended Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Employee Stock Purchase Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;The Company&#x2019;s board of directors and stockholders approved and adopted the Genprex &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), which became effective on &lt;em style="font: inherit;"&gt; April 3, 2018.&#160;&lt;/em&gt;The ESPP has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been utilized as a benefit available to the Company&#x2019;s employees.&#160;The ESPP authorizes the issuance of 105&#160;shares of common stock pursuant to purchase rights that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted to eligible employees. The number of shares of common stock reserved for issuance under the ESPP is automatically increased on &lt;em style="font: inherit;"&gt; January 1 &lt;/em&gt;of each calendar year, beginning on &lt;em style="font: inherit;"&gt; January 1, 2019, &lt;/em&gt;by 2% of the total number of shares of common stock outstanding on &lt;em style="font: inherit;"&gt; December 31 &lt;/em&gt;of the preceding calendar year, or a lesser number of shares determined by the administrator of the ESPP. The administrator of the ESPP determined &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to increase the number of &lt;span style="color:#000000;"&gt;shares reserved for issuance under the ESPP on&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; January 1, 2025&lt;/em&gt;&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;,&#160;Genprex had&#160;outstanding stock options to purchase&#160;&lt;/span&gt;5,705&lt;span style="background-color:#ffffff;"&gt; shares of common stock that have been granted to various executives, employees, non-employee directors, and independent contractors of the Company, including outstanding stock options to purchase &lt;/span&gt;509&lt;span style="background-color:#ffffff;"&gt;&#160;shares of common stock issued as inducement grants, outside of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, associated with the hiring of new executives in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&#160;These options vest immediately or over periods ranging from 12&#160;to 48&#160;months, are exercisable for a period of up to &lt;span style="-sec-ix-hidden:c138417458"&gt;ten&lt;/span&gt; years, and enable the holders to purchase shares of the Company&#x2019;s common stock at exercise prices ranging from&#160;$900.00&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;to&#160;$19,600.00&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;per share. The per-share fair values of these options range from&#160;$631.00 t&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;o&#160;$15,860.00&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;The Company did &lt;span style="-sec-ix-hidden:c138417464"&gt;&lt;span style="-sec-ix-hidden:c138417465"&gt;not&lt;/span&gt;&lt;/span&gt; issue stock options for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; or &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;. During the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company cancelled&#160;stock options to purchase&#160;1&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;share&#160;of common stock with an exercise price&#160;of&#160;$4,280.00&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;per share in connection with the termination&#160;of an employee.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;The Company did &lt;span style="-sec-ix-hidden:c138417471"&gt;&lt;span style="-sec-ix-hidden:c138417472"&gt;not&lt;/span&gt;&lt;/span&gt; issue stock options for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; or &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company cancelled&#160;stock options to purchase&#160;9&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock with a weighted average&#160;exercise price of&#160;$2,766.67&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;per share in connection with the termination&#160;of employees.&#160;During&#160;the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company cancelled&#160;stock options to purchase&#160;41&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock with a weighted average&#160;exercise price of&#160;$2,497.07&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;per share in connection with the termination&#160;of employees (inclusive of the options cancelled during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;described in the immediately preceding sentence).&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;The weighted average remaining contractual term for the outstanding options at&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;and&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;is&#160;4.37&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;and 5.11&#160;years, respectively.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;div style="font-size: 10pt;"&gt;
     &#160;
   &lt;/div&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0"&gt;&lt;span style="background-color:#ffffff;"&gt;Stock option activity for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months&#160;ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt;&#160;respectively, is as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at January 1,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,706&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c138417631"&gt;6,081.61&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c138417633"&gt;6,054.32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Options expired or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,280.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,620.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at March 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;5,705&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;span style="-sec-ix-hidden:c138417639"&gt;6,081.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;5,741&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;span style="-sec-ix-hidden:c138417641"&gt;6,061.27&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Options expired or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,734.78&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at June 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;5,705&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&lt;span style="-sec-ix-hidden:c138417647"&gt;6,081.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;5,718&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&lt;span style="-sec-ix-hidden:c138417649"&gt;6,074.65&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Options expired or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,766.67&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at September 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,705&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c138417655"&gt;6,081.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,709&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c138417657"&gt;6,079.87&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;During&#160;the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;,&#160;the Company cancelled&#160;240&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;RSUs associated with the termination of an employee.&#160;During&#160;the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;,&#160;the Company&#160;(i) granted&#160;1,600&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;RSUs to non-executive employees, (ii) withheld&#160;328&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares to cover taxes associated with the vesting of employee issued RSUs,&#160;(iii) cancelled&#160;246&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;RSUs associated with the termination of an employee, and (iv) issued&#160;1,790 s&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;hares of common stock associated with the vesting of RSUs to employees.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;During&#160;the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company cancelled&#160;1&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;RSU&#160;associated with the termination of an employee.&#160;During&#160;the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months&#160;ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company (i) withheld&#160;202&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares to cover taxes associated with the vesting of employee issued RSUs,&#160;(ii) cancelled&#160;7&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;RSUs associated with the termination of employees, and (iii) issued&#160;636&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;shares of common stock&#160;associated with the vesting of RSUs to executives, employees, and non-employee directors (inclusive of the RSUs described in the immediately preceding sentence during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;).&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;A summary of the RSU activity under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan during the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively, is presented below. These amounts include RSUs granted to executives, other employees, and board members.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Units&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grant Date Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Units&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grant Date Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at January 1,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,124&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;362.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,049&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,977.29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Restricted stock units granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Restricted stock units vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,813.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;245&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Restricted stock units forfeited or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,861.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;127&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at March 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,487&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;677&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,799.97&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock units vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,590&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;54.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;391&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,434.22&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock units forfeited or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;297&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;54.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at June 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;22.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;205&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock units forfeited or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;240&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;22.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at September 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,360&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;22.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;204&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline; font-size: 10pt; text-align: justify;"&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s total share-based compensation was approximately $&lt;/span&gt;0.02&lt;span style="background-color:#ffffff;"&gt;&#160;million,&#160;including $&lt;/span&gt;0.01&lt;span style="background-color:#ffffff;"&gt; million of R&amp;amp;D expense and&#160;$&lt;/span&gt;0.01&lt;span style="background-color:#ffffff;"&gt; million of G&amp;amp;A expense,&#160;and $&lt;/span&gt;0.7&lt;span style="background-color:#ffffff;"&gt; million, including $&lt;/span&gt;0.1&lt;span style="background-color:#ffffff;"&gt; million of R&amp;amp;D expense and&#160;$&lt;/span&gt;0.6&lt;span style="background-color:#ffffff;"&gt; million of G&amp;amp;A expense,&#160;respectively, which&#160;represents the expected vesting of options or RSUs issued to executives, other employees, board members, and service providers, as well as the issuance of shares to service providers.&#160;As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;,&#160;the Company&#x2019;s total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, other employees, board&#160;members, and service providers and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet recognized was approximately $&lt;/span&gt;0.06&lt;span style="background-color:#ffffff;"&gt;&#160;million. The Company expects to record this stock-based compensation expense over the next &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years using a graded vesting method. As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;,&#160;the weighted average term over which these expenses are expected to be recognized is&#160;1.39&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;years.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s total share-based compensation was approximately $&lt;/span&gt;0.4&lt;span style="background-color:#ffffff;"&gt;&#160;million,&#160;including $&lt;/span&gt;0.2&lt;span style="background-color:#ffffff;"&gt;&#160;million of R&amp;amp;D expense and&#160;$&lt;/span&gt;0.2&lt;span style="background-color:#ffffff;"&gt; million of G&amp;amp;A expense,&#160;and $&lt;/span&gt;3.0&lt;span style="background-color:#ffffff;"&gt; million, including $&lt;/span&gt;0.5&lt;span style="background-color:#ffffff;"&gt;&#160;million of R&amp;amp;D expense and&#160;$&lt;/span&gt;2.5&lt;span style="background-color:#ffffff;"&gt; million of G&amp;amp;A expense,&#160;respectively, which&#160;represents the expected vesting of options or RSUs issued to executives, other employees, board members, and service providers, as well as the issuance of shares to service providers.&#160;As of&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company&#x2019;s total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, other employees, board&#160;members, and service providers and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet recognized was approximately $&lt;/span&gt;0.6&lt;span style="background-color:#ffffff;"&gt; million. The Company expects to record this stock-based compensation expense over the next &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years using a graded vesting method. As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;,&#160;the weighted average term over which these expenses are expected to be recognized is&#160;0.58&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;years.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="background-color:#ffffff;"&gt;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, there are&#160;&lt;span style="-sec-ix-hidden:c138417530"&gt;no&lt;/span&gt;&#160;performance-based stock option awards outstanding and &lt;span style="-sec-ix-hidden:c138417531"&gt;one&lt;/span&gt; performance-based warrant outstanding issued to a service provider. The Company&#x2019;s total compensation cost related to the non-vested performance-based warrant&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet recognized was approximately $0.3 million.&#160;The entirety of this warrant &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be recognized and recorded upon the achievement of certain clinical milestones.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-02-02_2024-02-02_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c138417236"
      unitRef="Pure">40</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2025-10-21_2025-10-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417241"
      unitRef="Pure">50</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-03-21_2024-03-21_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417245"
      unitRef="Share">3300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417246"
      unitRef="Share">27543</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024CommonWarrantsMember"
      decimals="INF"
      id="c138417247"
      unitRef="Share">30843</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <gnpx:EquityOfferingCombinedPurchasePrice
      contextRef="d_2024-03-21_2024-03-21_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417248"
      unitRef="USDPerShare">210.75</gnpx:EquityOfferingCombinedPurchasePrice>
    <gnpx:ClassOfWarrantOrRightCombinedPurchasePrice
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantAndCommonWarrantMember"
      decimals="INF"
      id="c138417249"
      unitRef="USD">210.75</gnpx:ClassOfWarrantOrRightCombinedPurchasePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417250"
      unitRef="USDPerShare">0.005</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-March2024CommonWarrantsMember"
      decimals="INF"
      id="c138417251"
      unitRef="USDPerShare">204.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-03-01_2024-03-31_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417253"
      unitRef="USD">5.8</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c138417254"
      unitRef="Share">3886</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417255"
      unitRef="USDPerShare">2200</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-07-31_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417256"
      unitRef="USDPerShare">1770</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightAmendmentPricePerWarrant
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417257"
      unitRef="USDPerShare">6.25</gnpx:ClassOfWarrantOrRightAmendmentPricePerWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-03-21_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417258"
      unitRef="USDPerShare">204.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-01-01_2024-12-31_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417260"
      unitRef="Share">27543</gnpx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <gnpx:BrokerageCommissionsPercentageOfGrossProceeds
      contextRef="d_2023-12-13_2023-12-13_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="2"
      id="c138417268"
      unitRef="Pure">0.03</gnpx:BrokerageCommissionsPercentageOfGrossProceeds>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-07-01_2025-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="-3"
      id="c138417269"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417273"
      unitRef="Share">338811</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417274"
      unitRef="USD">6895947</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <gnpx:EquityIssuanceMaximumAmountAvailableForIssuance
      contextRef="d_2025-06-11_2025-06-11_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="-5"
      id="c138417279"
      unitRef="USD">12500000</gnpx:EquityIssuanceMaximumAmountAvailableForIssuance>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417285"
      unitRef="USD">243000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072287">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 17.5%; margin-left: 17.5%; width: 65%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading GFJY4-DHU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DJN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurement at September 30, 2025&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DHU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DJN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Carrying Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 36%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Derivative liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;243,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;243,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Totals liabilities measured and recorded at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;243,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;243,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="c138417556"
      unitRef="USD">243000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="c138417557"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="c138417558"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="c138417559"
      unitRef="USD">243000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2025-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="c138417560"
      unitRef="USD">243000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2025-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="c138417561"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2025-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="c138417562"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2025-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="INF"
      id="c138417563"
      unitRef="USD">243000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072288">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 27.5%; margin-left: 27.5%; width: 45%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading GFJY4-DHU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;September 30, 2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closing stock price:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;180.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years):&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.70&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c138417564"
      unitRef="Pure">0.17</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="1"
      id="c138417565"
      unitRef="Pure">1.80</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c138417566"
      unitRef="Pure">1.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2025-09-30_DerivativeInstrumentRiskAxis-ElocDerivativeMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="c138417567"
      unitRef="Pure">0.036</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2025-07-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417287"
      unitRef="Share">341224</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-07-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417288"
      unitRef="USD">2943745</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-09-30_StatementClassOfStockAxis-CommitmentSharesMember_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417291"
      unitRef="Share">23737</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-09-30_StatementClassOfStockAxis-CommitmentSharesMember_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417292"
      unitRef="USD">365550</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417294"
      unitRef="Share">422380</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417295"
      unitRef="USD">3818631</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2025-07-01_2025-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417301"
      unitRef="Share">100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-07-01_2025-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417302"
      unitRef="USD">1335</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-07-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417303"
      unitRef="Share">341224</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-07-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417304"
      unitRef="USD">2943745</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2025-01-01_2025-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417307"
      unitRef="Share">300</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2025-01-01_2025-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417308"
      unitRef="USD">6990</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417309"
      unitRef="Share">1785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417310"
      unitRef="USD">21922</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417311"
      unitRef="Share">338811</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417312"
      unitRef="USD">6895947</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-09-30_StatementClassOfStockAxis-CommitmentSharesMember_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417314"
      unitRef="Share">23737</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417316"
      unitRef="Share">422380</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-09-30_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417317"
      unitRef="USD">3818631</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-07-01_2024-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417321"
      unitRef="Share">100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-07-01_2024-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417322"
      unitRef="USD">9650</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <gnpx:StockIssuedDuringPeriodSharesIssuedDueToExerciseOfWarrants
      contextRef="d_2024-07-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417323"
      unitRef="Share">15580</gnpx:StockIssuedDuringPeriodSharesIssuedDueToExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-07-01_2024-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417324"
      unitRef="Share">42990</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-07-01_2024-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417325"
      unitRef="USD">1215105</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417328"
      unitRef="Share">203</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417329"
      unitRef="USD">25904</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-ServiceProvidersMember"
      decimals="INF"
      id="c138417330"
      unitRef="Share">725</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-09-30_TitleOfIndividualAxis-ServiceProvidersMember"
      decimals="INF"
      id="c138417331"
      unitRef="USD">179550</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2024-01-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417332"
      unitRef="Share">633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="d_2024-01-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417333"
      unitRef="USD">96524</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138417334"
      unitRef="Share">1294</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417335"
      unitRef="Share">46370</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417336"
      unitRef="USD">2117752</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-March2024RegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417338"
      unitRef="Share">3300</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-March2024RegisteredDirectOfferingMember"
      decimals="-5"
      id="c138417339"
      unitRef="USD">5800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <gnpx:StockIssuedDuringPeriodSharesIssuedDueToExerciseOfWarrants
      contextRef="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417340"
      unitRef="Share">27543</gnpx:StockIssuedDuringPeriodSharesIssuedDueToExerciseOfWarrants>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417342"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417344"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417348"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417350"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417352"
      unitRef="Share">1004247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417353"
      unitRef="Share">217234</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072289">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; margin-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; margin-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; margin-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; margin-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at January 1,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39,633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;503.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,052&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,054.81&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrants issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;64,124&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;118.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at March 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;39,633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;503.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;67,176&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;297.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Outstanding at June 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;39,633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;503.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;55,214&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;361.60&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;15,580&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Warrants cancelled or expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,620.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at September 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,608&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;499.26&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,634&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;503.74&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417581"
      unitRef="Share">39633</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417582"
      unitRef="USDPerShare">503.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c138417583"
      unitRef="Share">3052</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c138417584"
      unitRef="USDPerShare">4054.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138417585"
      unitRef="Share">0</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138417586"
      unitRef="USDPerShare">0</gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138417587"
      unitRef="Share">64124</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138417588"
      unitRef="USDPerShare">118.37</gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c138417589"
      unitRef="Share">39633</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c138417590"
      unitRef="USDPerShare">503.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c138417591"
      unitRef="Share">67176</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c138417592"
      unitRef="USDPerShare">297.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138417593"
      unitRef="Share">0</gnpx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138417594"
      unitRef="USDPerShare">0</gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138417595"
      unitRef="Share">11962</gnpx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138417596"
      unitRef="USDPerShare">0.01</gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c138417597"
      unitRef="Share">39633</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c138417598"
      unitRef="USDPerShare">503.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c138417599"
      unitRef="Share">55214</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c138417600"
      unitRef="USDPerShare">361.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138417601"
      unitRef="Share">0</gnpx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138417602"
      unitRef="USDPerShare">0</gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417603"
      unitRef="Share">15580</gnpx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417604"
      unitRef="USDPerShare">0.01</gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
    <gnpx:WarrantsOrRightsCancelledDuringPeriod
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138417605"
      unitRef="Share">25</gnpx:WarrantsOrRightsCancelledDuringPeriod>
    <gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138417606"
      unitRef="USDPerShare">7620</gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice>
    <gnpx:WarrantsOrRightsCancelledDuringPeriod
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417607"
      unitRef="Share">0</gnpx:WarrantsOrRightsCancelledDuringPeriod>
    <gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417608"
      unitRef="USDPerShare">0</gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417609"
      unitRef="Share">39608</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417610"
      unitRef="USDPerShare">499.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c138417611"
      unitRef="Share">39634</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c138417612"
      unitRef="USDPerShare">503.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:WarrantsOrRightsCancelledDuringPeriod
      contextRef="d_2025-07-01_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417362"
      unitRef="Share">25</gnpx:WarrantsOrRightsCancelledDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417364"
      unitRef="USDPerShare">7620</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="-5"
      id="c138417369"
      unitRef="USD">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="-5"
      id="c138417374"
      unitRef="USD">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <gnpx:StockIssuedDuringPeriodSharesIssuedDueToExerciseOfWarrants
      contextRef="d_2024-07-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417378"
      unitRef="Share">15580</gnpx:StockIssuedDuringPeriodSharesIssuedDueToExerciseOfWarrants>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417382"
      unitRef="Share">27543</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-March2024PrefundedWarrantsMember"
      decimals="INF"
      id="c138417383"
      unitRef="USDPerShare">0.005</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-March2024CommonWarrantsMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c138417384"
      unitRef="Share">30843</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-March2024CommonWarrantsMember"
      decimals="INF"
      id="c138417385"
      unitRef="USDPerShare">204.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember"
      decimals="INF"
      id="c138417386"
      unitRef="Share">1851</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember"
      decimals="INF"
      id="c138417387"
      unitRef="USDPerShare">260.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417388"
      unitRef="Share">3885</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-AmendedRegisteredDirectOfferingMember"
      decimals="INF"
      id="c138417389"
      unitRef="USDPerShare">204.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:StockIssuedDuringPeriodSharesIssuedDueToExerciseOfWarrants
      contextRef="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember"
      decimals="INF"
      id="c138417391"
      unitRef="Share">11963</gnpx:StockIssuedDuringPeriodSharesIssuedDueToExerciseOfWarrants>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-07-01_2024-09-30_ClassOfWarrantOrRightAxis-VestingOfWarrantsForServiceProviderMember"
      decimals="INF"
      id="c138417395"
      unitRef="USD">2280</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-09-30_ClassOfWarrantOrRightAxis-VestingOfWarrantsForServiceProviderMember"
      decimals="INF"
      id="c138417396"
      unitRef="USD">18039</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember"
      decimals="INF"
      id="c138417397"
      unitRef="Share">39608</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember"
      decimals="INF"
      id="c138417398"
      unitRef="USDPerShare">499.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c138417400"
      unitRef="USDPerShare">204.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c138417401"
      unitRef="USDPerShare">14440</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:WarrantsOrRightsFairValuePerShare
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c138417402"
      unitRef="USDPerShare">60.67</gnpx:WarrantsOrRightsFairValuePerShare>
    <gnpx:WarrantsOrRightsFairValuePerShare
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-OutstandingWarrantsMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c138417403"
      unitRef="USDPerShare">9250.2</gnpx:WarrantsOrRightsFairValuePerShare>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072290">
    &lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 40%; margin-left: 0pt; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Nine Months Ended September 30, 2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years):&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;5.0&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate:&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;4.52%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility:&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;87.49%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 41%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield:&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;0%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2024-01-01_2024-09-30" id="c138417614">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2024-01-01_2024-09-30"
      decimals="4"
      id="c138417615"
      unitRef="Pure">0.0452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-01-01_2024-09-30"
      decimals="4"
      id="c138417616"
      unitRef="Pure">0.8749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2024-01-01_2024-09-30"
      decimals="-3"
      id="c138417617"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c138417413"
      unitRef="Share">2080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2018-04-03_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c138417416"
      unitRef="Share">1314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear
      contextRef="i_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="2"
      id="c138417422"
      unitRef="Pure">0.05</gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2025-08-15_2025-08-15_PlanNameAxis-Amended2018EquityIncentivePlanMember"
      decimals="INF"
      id="c138417430"
      unitRef="Share">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2024-01-01_2024-01-01_PlanNameAxis-Amended2018EquityIncentivePlanMember"
      decimals="INF"
      id="c138417441"
      unitRef="Share">1486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2025-01-01_2025-01-01_PlanNameAxis-Amended2018EquityIncentivePlanMember"
      decimals="INF"
      id="c138417442"
      unitRef="Share">10861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2025-09-30_PlanNameAxis-Amended2018EquityIncentivePlanMember"
      decimals="INF"
      id="c138417443"
      unitRef="Share">144588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c138417448"
      unitRef="Share">105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear
      contextRef="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c138417449"
      unitRef="Pure">0.02</gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417451"
      unitRef="Share">5705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-09-30_PlanNameAxis-The2018EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c138417452"
      unitRef="Share">509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-01_2025-09-30_RangeAxis-MinimumMember"
      id="c138417456">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-01_2025-09-30_RangeAxis-MaximumMember"
      id="c138417457">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-09-30_RangeAxis-MinimumMember"
      decimals="INF"
      id="c138417459"
      unitRef="USDPerShare">900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-09-30_RangeAxis-MaximumMember"
      decimals="INF"
      id="c138417460"
      unitRef="USDPerShare">19600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-09-30_RangeAxis-MinimumMember"
      decimals="INF"
      id="c138417461"
      unitRef="USDPerShare">631</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-09-30_RangeAxis-MaximumMember"
      decimals="INF"
      id="c138417462"
      unitRef="USDPerShare">15860</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138417469"
      unitRef="Share">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138417470"
      unitRef="USDPerShare">4280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417476"
      unitRef="Share">9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417477"
      unitRef="USDPerShare">2766.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138417479"
      unitRef="Share">41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138417480"
      unitRef="USDPerShare">2497.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2025-01-01_2025-09-30" id="c138417482">P4Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2024-01-01_2024-12-31" id="c138417483">P5Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072291">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at January 1,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,706&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c138417631"&gt;6,081.61&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c138417633"&gt;6,054.32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Options expired or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,280.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,620.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at March 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;5,705&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;span style="-sec-ix-hidden:c138417639"&gt;6,081.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;5,741&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0px;"&gt;&lt;span style="-sec-ix-hidden:c138417641"&gt;6,061.27&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Options expired or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,734.78&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at June 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;5,705&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&lt;span style="-sec-ix-hidden:c138417647"&gt;6,081.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;5,718&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&lt;span style="-sec-ix-hidden:c138417649"&gt;6,074.65&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Options expired or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,766.67&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at September 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,705&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c138417655"&gt;6,081.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,709&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c138417657"&gt;6,079.87&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c138417630"
      unitRef="Share">5706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c138417632"
      unitRef="Share">5750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138417634"
      unitRef="Share">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-03-31"
      decimals="INF"
      id="c138417635"
      unitRef="USDPerShare">4280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138417636"
      unitRef="Share">9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-03-31"
      decimals="INF"
      id="c138417637"
      unitRef="USDPerShare">1620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c138417638"
      unitRef="Share">5705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c138417640"
      unitRef="Share">5741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138417642"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c138417643"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138417644"
      unitRef="Share">23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c138417645"
      unitRef="USDPerShare">2734.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c138417646"
      unitRef="Share">5705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c138417648"
      unitRef="Share">5718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138417650"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138417651"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417652"
      unitRef="Share">9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417653"
      unitRef="USDPerShare">2766.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-09-30"
      decimals="INF"
      id="c138417654"
      unitRef="Share">5705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c138417656"
      unitRef="Share">5709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2025-07-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c138417488"
      unitRef="Share">240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c138417490"
      unitRef="Share">1600</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417491"
      unitRef="Share">328</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c138417492"
      unitRef="Share">246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:SharesIssued
      contextRef="i_2025-09-30_StatementEquityComponentsAxis-CommonStockMember_TitleOfIndividualAxis-BoardMembersMember"
      decimals="INF"
      id="c138417493"
      unitRef="Share">1790</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2024-07-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c138417495"
      unitRef="Share">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="d_2024-01-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417497"
      unitRef="Share">202</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2024-01-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c138417498"
      unitRef="Share">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:SharesIssued
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember_TitleOfIndividualAxis-ExecutivesEmployeesAndNonemployeeDirectorsMember"
      decimals="INF"
      id="c138417499"
      unitRef="Share">636</us-gaap:SharesIssued>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072292">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Units&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grant Date Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Units&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grant Date Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at January 1,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,124&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;362.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,049&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,977.29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Restricted stock units granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Restricted stock units vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,813.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;245&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Restricted stock units forfeited or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,861.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;127&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at March 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,487&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;677&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,799.97&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock units vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,590&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;54.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;391&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,434.22&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock units forfeited or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;297&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;54.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at June 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;22.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;205&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock units forfeited or cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;240&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;22.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Outstanding at September 30,&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,360&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;22.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;204&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,300.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417670"
      unitRef="Share">2124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417671"
      unitRef="USDPerShare">362.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417672"
      unitRef="Share">1049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417673"
      unitRef="USDPerShare">2977.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2025-01-01_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417674"
      unitRef="Share">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417675"
      unitRef="USDPerShare">22.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2024-01-01_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417676"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417677"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="d_2025-01-01_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417678"
      unitRef="Share">200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417679"
      unitRef="USDPerShare">2813.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="d_2024-01-01_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417680"
      unitRef="Share">245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417681"
      unitRef="USDPerShare">3300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="d_2025-01-01_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417682"
      unitRef="Share">37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417683"
      unitRef="USDPerShare">2861.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="d_2024-01-01_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417684"
      unitRef="Share">127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417685"
      unitRef="USDPerShare">3300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417686"
      unitRef="Share">3487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2025-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417687"
      unitRef="USDPerShare">39.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417688"
      unitRef="Share">677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417689"
      unitRef="USDPerShare">2799.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417690"
      unitRef="Share">1590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417691"
      unitRef="USDPerShare">54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417692"
      unitRef="Share">391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417693"
      unitRef="USDPerShare">2434.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417694"
      unitRef="Share">297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417695"
      unitRef="USDPerShare">54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417696"
      unitRef="Share">81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417697"
      unitRef="USDPerShare">3300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417698"
      unitRef="Share">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417699"
      unitRef="USDPerShare">22.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417700"
      unitRef="Share">205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417701"
      unitRef="USDPerShare">3300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="d_2025-07-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417702"
      unitRef="Share">240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2025-07-01_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417703"
      unitRef="USDPerShare">22.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="d_2024-07-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417704"
      unitRef="Share">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2024-07-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417705"
      unitRef="USDPerShare">3300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417706"
      unitRef="Share">1360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2025-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417707"
      unitRef="USDPerShare">22.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417708"
      unitRef="Share">204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c138417709"
      unitRef="USDPerShare">3300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-07-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-4"
      id="c138417508"
      unitRef="USD">20000.00</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-07-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-4"
      id="c138417509"
      unitRef="USD">10000.00</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-07-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-4"
      id="c138417510"
      unitRef="USD">10000.00</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c138417511"
      unitRef="USD">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c138417512"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="c138417513"
      unitRef="USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-4"
      id="c138417515"
      unitRef="USD">60000.00</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2025-01-01_2025-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c138417517">P1Y4M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-07-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c138417520"
      unitRef="USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-07-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c138417521"
      unitRef="USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-07-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="c138417522"
      unitRef="USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-6"
      id="c138417523"
      unitRef="USD">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c138417524"
      unitRef="USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="c138417525"
      unitRef="USD">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c138417527"
      unitRef="USD">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c138417529">P0Y6M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <gnpx:WarrantNonvestedAwardCostNotYetRecognizedAmount
      contextRef="i_2025-09-30_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember"
      decimals="-5"
      id="c138417533"
      unitRef="USD">300000</gnpx:WarrantNonvestedAwardCostNotYetRecognizedAmount>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072293">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt;&#160;- &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Savings Plan&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; Genprex established a defined contribution savings plan under Section&#160;&lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) of the Internal Revenue Code (&lt;em style="font: inherit;"&gt;&#x201c;401&lt;/em&gt;(k) Plan&#x201d;) and established an employer matching program for participants in the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan. The &lt;em style="font: inherit;"&gt;401&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;(k) Plan covers all&#160;employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a&#160;pre-tax basis. The Company incurred&#160;$23,803&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;and&#160;$77,135&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;of expense for matching contributions to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, respectively.&#160;The Company incurred&#160;$31,930&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;and&#160;$105,848&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;of expense for matching contributions to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt; months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2024&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;,&#160;respectively.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
  </us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138417717"
      unitRef="USD">23803</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138417718"
      unitRef="USD">77135</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417722"
      unitRef="USD">31930</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138417723"
      unitRef="USD">105848</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072294">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;&#160;- Related Party Transactions&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Introgen Research Institute&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Introgen Research Institute (&#x201c;IRI&#x201d;) is a Texas-based technology company formed by Rodney Varner, who prior to his passing in &lt;em style="font: inherit;"&gt; May 2024, &lt;/em&gt;was the Company&#x2019;s President, Chief Executive Officer and Chairman of the Board&#160;and who was IRI&#x2019;s sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In &lt;em style="font: inherit;"&gt; April 2009, &lt;/em&gt;prior to Mr. Varner becoming an officer and director of Genprex in &lt;em style="font: inherit;"&gt; August 2012, &lt;/em&gt;the Company entered into an Assignment and Collaboration Agreement with IRI, providing Genprex with the exclusive right to commercialize a portfolio of intellectual property. This agreement was amended in &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; to include additional sublicensing of additional intellectual property made available to IRI from MD Anderson (see Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &#x2013; Commitments and Contingences &#x2013; Commitments &#x2013; MD Anderson Cancer Center).&#160;There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;amounts incurred or due under this agreement at &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&#160;&lt;/p&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072295">
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt;&#160;- Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Commitments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;MD Anderson Cancer Center&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; July 2018, &lt;/em&gt;Genprex entered into a &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on the combination of REQORSA with an immunotherapy&#160;with a projected total cost of approximately $2 million. This agreement&#160;was extended beyond the original expiration date, expiring in &lt;em style="font: inherit;"&gt; May 2022 &lt;/em&gt;after giving effect to such extension. In &lt;em style="font: inherit;"&gt; August 2022, &lt;/em&gt;the Company entered into a&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;-year sponsored research agreement with MD Anderson (the &lt;em style="font: inherit;"&gt; &#x201c;August 2022 &lt;/em&gt;SRA&#x201d;) to sponsor preclinical studies focused on REQORSA and &lt;em style="font: inherit;"&gt;NPRL2&lt;/em&gt; in oncology&#160;to resensitize NSCLC and SCLC to targeted therapies and immunotherapies&#160;with an initial projected total cost of approximately $2.9&#160;million. On &lt;em style="font: inherit;"&gt; June 7, 2024, &lt;/em&gt;the Company amended the &lt;em style="font: inherit;"&gt; August 2022 &lt;/em&gt;SRA with MD Anderson to (i) extend the sponsored research program&#160;an additional &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months, (ii) amend the quarterly budget from approximately $240,000 to $165,000 per quarter, and (iii) amend the total commitment from $2.9 million to approximately $2.76&#160;milli&lt;span style="background-color:#ffffff;"&gt;on. The Company incurred &lt;/span&gt;$165,701&lt;span style="background-color:#ffffff;"&gt;&#160;of expense&#160;from this agreement during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;. As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company has paid&#160;approximately &lt;/span&gt;$2.1&lt;span style="background-color:#ffffff;"&gt;&#160;million toward this $2.76&#160;million commitment.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt;2011,&lt;/em&gt; the Company agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated with certain technologies&#160;and intellectual property originally licensed to another party under the &lt;em style="font: inherit;"&gt;1994&lt;/em&gt; License Agreement with MD Anderson (&#x201c;Original MD Anderson License Agreement&#x201d;). These technologies and intellectual property were later sublicensed to IRI (the &#x201c;IRI Sublicense&#x201d;). The Company also agreed to pay royalties of 1% on sales of certain licensed products for a period of 21 years following the termination of the later of the Original MD Anderson License Agreement and the&#160;IRI Sublicense. The Company assumed patent prosecution costs and an annual minimum royalty of $20,000&#160;payable to the National Institutes of Health (&#x201c;NIH&#x201d;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 3, 2021, &lt;/em&gt;the Company entered into an amendment (the &#x201c;MD License Amendment&#x201d;) to the Patent and Technology License Agreement dated &lt;em style="font: inherit;"&gt; May 4, 2020, &lt;/em&gt;with MD Anderson. The MD License&#160;Amendment grants Genprex&#160;a worldwide, exclusive, sublicensable license to an additional portfolio of &lt;em style="font: inherit;"&gt;six&lt;/em&gt; patents and &lt;em style="font: inherit;"&gt;one&lt;/em&gt; patent application and related technology for methods for treating&#160;cancer by administration of a &lt;em style="font: inherit;"&gt;TUSC2&lt;/em&gt; therapy in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to &lt;em style="font: inherit;"&gt;TUSC2&lt;/em&gt; therapy. Pursuant to the MD License&#160;Amendment, the Company agreed to (i) pay &lt;span style="background-color:#ffffff;"&gt;annual maintenance fees ranging from the mid &lt;em style="font: inherit;"&gt;five&lt;/em&gt; figures to the low &lt;em style="font: inherit;"&gt;six&lt;/em&gt; figures, (ii) total milestone payments of $6,150,000, (iii) a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time fee in the mid &lt;em style="font: inherit;"&gt;five&lt;/em&gt;&#160;figures and (iv) certain patent related expenses.&#160;The Company incurred &lt;/span&gt;$155,000&lt;span style="background-color:#ffffff;"&gt;&#160;and&#160;&lt;/span&gt;$50,000&lt;span style="background-color:#ffffff;"&gt; of expense for each of the &lt;/span&gt;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively.&#160;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, the Company has paid&#160;approximately&#160;&lt;/span&gt;$525,000&lt;span style="background-color:#ffffff;"&gt; toward the above-described commitment under this agreement.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;National Institutes of Health&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Genprex has a royalty obligation to the National Institutes of Health to be paid upon the&#160;Company&#x2019;s receipt of FDA approval using NIH technology.&#160;The $240,000 contingent obligation, which increases annually by $20,000, and is&#160;$400,000 and&#160;$380,000 as of &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;respectively, will be recognized if and when it is probable the Company will obtain&#160;regulatory approval (the event that triggers the payment obligation).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;New York University&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; April 25, 2025, &lt;/em&gt;the Company and NYU entered into the NYU License Agreement, which granted Genprex patent exclusivity and commercial rights worldwide relating to Genprex&#x2019;s lead drug candidate REQORSA for the potential treatment of mesothelioma.&#160; Pursuant to the NYU License Agreement, Genprex agreed to pay: (i) an initial license fee of $5,000, (ii) annual license fees of $35,000 for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt;second&lt;/em&gt; year anniversaries, $25,000 for the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; anniversary and $50,000 for the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; year and each subsequent year following the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; anniversary of the agreement thereafter,&#160;(iii) running low single digit percentage royalties ranging from 1% to 2% of net sales, (iv) certain potential technical milestone payments through regulatory approval&#160;up to an aggregate of approximately $400,000, and (v) certain patent related expense&lt;span style="background-color:#ffffff;"&gt;s.&#160;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, Genprex has paid&#160;approximately&#160;$5,000&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;toward this commitment.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;University of Michigan&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; November 11, 2024, &lt;/em&gt;the Company and the University of Michigan entered into the UM License Agreement, which granted Genprex a worldwide, exclusive license to the University of Michigan&#x2019;s patent rights in a co-owned patent application relating to the use of REQORSA in combination with ALK-inhibitors for the treatment of ALK-&lt;em style="font: inherit;"&gt;EML4&lt;/em&gt; positive translocated lung cancer. Genprex agreed to pay: (i) an initial license issue fee of $30,000, (ii) running low single digit percentage royalties ranging from 1% to 3% of net sales, (iii) minimum annual royalties in a fixed cash amount of $15,000 for &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2026,&lt;/em&gt;&#160;and $30,000 for &lt;em style="font: inherit;"&gt;2027&lt;/em&gt; and each year thereafter during the term of the UM License Agreement, (iv) a tiered&#160;double digit percentage share of non-royalty sublicense income ranging from 10% to 40%, and (v) certain potential clinical milestone payments through FDA regulatory approval up to an aggregate of approximately $350,000 in addition to certain potential commercial sales milestones.&#160;&lt;span style="background-color:#ffffff;"&gt;The Company incurred &lt;span style="-sec-ix-hidden:c138417795"&gt;no&lt;/span&gt; expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;.&#160;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, Genprex has paid&#160;approximately&#160;$30,000&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;toward this commitment.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;University of Pittsburgh&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Pursuant to the New UP License Agreement dated &lt;em style="font: inherit;"&gt; February 17, 2025, &lt;/em&gt;by and between Genprex and the University of Pittsburgh, Genprex agreed to pay (i) an initial licensing fee of $10,000, (ii) annual maintenance fees of $65,000 for the first, &lt;em style="font: inherit;"&gt;second&lt;/em&gt; and &lt;em style="font: inherit;"&gt;third&lt;/em&gt;&#160;years, and $120,000 for the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; year and each subsequent year following the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; anniversary of the agreement thereafter until the anniversary prior to the year of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale, (iii) royalties ranging from 1.5% to 3%&#160;of net sales of licensed technologies, (iv) an annual minimum&#160;royalty payment of $250,000 per year beginning in the year of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $4,825,000 in milestone payments related to the usage of the licensed technologies to potentially treat Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) &lt;em style="font: inherit;"&gt;20&lt;/em&gt; years after&#160;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.&lt;span style="background-color:#ffffff;"&gt;&#160;The Company incurred &lt;span style="-sec-ix-hidden:c138417817"&gt;no&lt;/span&gt; expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;months ended &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;.&#160;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, Genprex has paid&#160;approximately&#160;$10,000&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;toward this commitment.&#160;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;UTHealth Houston&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; May 2, 2025, &lt;/em&gt;the Company and UTHealth Houston entered into the UTH License Agreement, which granted Genprex exclusivity and commercial rights worldwide relating to Genprex&#x2019;s lead drug candidate REQORSA for the potential treatment of glioblastoma.&#160; Pursuant to the UTH License Agreement, Genprex agreed to pay: (i) an initial license issue fee of $10,000 along with additional, staggered upfront license fees totaling another $40,000 and an annual license management fee of $3,000, (ii) running low single digit percentage royalties ranging from 0.10% to 0.25% of net product sales, (iii) minimum annual royalty of $25,000&#160;beginning after the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; year in which royalties obligations commence pursuant to the UTH License Agreement, (iv) certain potential clinical and regulatory milestone payments through FDA and international regulatory approvals up to an aggregate of approximately $360,000, and (v) certain patent related expenses&lt;span style="background-color:#ffffff;"&gt;.&#160;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, Genprex has paid&#160;approximately&#160;&lt;/span&gt;$10,000&lt;span style="background-color:#ffffff;"&gt; toward this commitment.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Contract Development and Manufacturing Organization&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Genprex entered into a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-year&#160;development services agreement in &lt;em style="font: inherit;"&gt; July 2022, &lt;/em&gt;amended in each of &lt;em style="font: inherit;"&gt; January 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 2023, &lt;/em&gt;with a contract development and manufacturing organization (&#x201c;CDMO&#x201d;) to manufacture good manufacturing practices (&#x201c;GMP&#x201d;) grade materials for use in the Company&#x2019;s clinical trials with a projected total cost at inception of approximately $4.5&#160;million. On &lt;em style="font: inherit;"&gt; April 2, 2024, &lt;/em&gt;the Company was informed by the&#160;CDMO that the CDMO&#160;was ceasing certain manufacturing operations subject to the development services agreement. On &lt;em style="font: inherit;"&gt; June 30, 2024, &lt;/em&gt;the development services agreement was terminated by mutual agreement&#160;and the CDMO returned $1.3 million to the Company and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional commitments are obligated&#160;or owed by the Company. The Company did &lt;span style="-sec-ix-hidden:c138417833"&gt;&lt;span style="-sec-ix-hidden:c138417838"&gt;not&lt;/span&gt;&lt;/span&gt; incur any expense from this agreement during each of the&#160;&lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt;&#160;respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Contingencies&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;From time to time, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;become subject to threatened and/or asserted claims arising in the ordinary course of its business. Management is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; aware of any pending matters, either individually or in the aggregate, that are reasonably likely to have a material impact on the Company&#x2019;s financial condition, results of operations or liquidity.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <gnpx:LongTermContractEstimatedCost
      contextRef="d_2018-07-01_2018-07-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="-6"
      id="c138417734"
      unitRef="USD">2000000</gnpx:LongTermContractEstimatedCost>
    <gnpx:LongTermContractEstimatedCost
      contextRef="d_2022-09-30_2022-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="-5"
      id="c138417737"
      unitRef="USD">2900000</gnpx:LongTermContractEstimatedCost>
    <gnpx:LongTermContractQuarterlyBudgetAllocated
      contextRef="d_2024-01-01_2024-06-06_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="INF"
      id="c138417739"
      unitRef="USD">240000</gnpx:LongTermContractQuarterlyBudgetAllocated>
    <gnpx:LongTermContractQuarterlyBudgetAllocated
      contextRef="d_2024-06-07_2024-06-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="INF"
      id="c138417740"
      unitRef="USD">165000</gnpx:LongTermContractQuarterlyBudgetAllocated>
    <gnpx:LongTermContractEstimatedCost
      contextRef="d_2024-01-01_2024-06-06_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="-5"
      id="c138417741"
      unitRef="USD">2900000</gnpx:LongTermContractEstimatedCost>
    <gnpx:LongTermContractEstimatedCost
      contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="-4"
      id="c138417742"
      unitRef="USD">2760000</gnpx:LongTermContractEstimatedCost>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-07-01_2025-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="INF"
      id="c138417743"
      unitRef="USD">165701</us-gaap:CostsAndExpenses>
    <gnpx:ContractPaymentsIncurredAndPaid
      contextRef="d_2025-07-01_2025-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="-5"
      id="c138417745"
      unitRef="USD">2100000</gnpx:ContractPaymentsIncurredAndPaid>
    <gnpx:LongTermContractEstimatedCost
      contextRef="d_2024-01-01_2024-12-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="-4"
      id="c138417746"
      unitRef="USD">2760000</gnpx:LongTermContractEstimatedCost>
    <gnpx:RoyaltyOnSalesPercentage
      contextRef="i_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="2"
      id="c138417749"
      unitRef="Pure">0.01</gnpx:RoyaltyOnSalesPercentage>
    <gnpx:RoyaltyTerms
      contextRef="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      id="c138417750">P21Y</gnpx:RoyaltyTerms>
    <gnpx:RoyaltyPaymentAnnualMinimum
      contextRef="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="INF"
      id="c138417751"
      unitRef="USD">20000</gnpx:RoyaltyPaymentAnnualMinimum>
    <gnpx:LicenseAgreementMilestonePayment
      contextRef="i_2021-03-03_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember"
      decimals="INF"
      id="c138417758"
      unitRef="USD">6150000</gnpx:LicenseAgreementMilestonePayment>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-01-01_2025-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember"
      decimals="INF"
      id="c138417761"
      unitRef="USD">155000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2024-01-01_2024-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember"
      decimals="INF"
      id="c138417762"
      unitRef="USD">50000</us-gaap:CostsAndExpenses>
    <gnpx:ContractPaymentsIncurredAndPaid
      contextRef="d_2025-01-01_2025-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember"
      decimals="INF"
      id="c138417765"
      unitRef="USD">525000</gnpx:ContractPaymentsIncurredAndPaid>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="INF"
      id="c138417766"
      unitRef="USD">240000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <gnpx:ContingentPaymentsAnnualIncrease
      contextRef="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="INF"
      id="c138417767"
      unitRef="USD">20000</gnpx:ContingentPaymentsAnnualIncrease>
    <us-gaap:OtherCommitment
      contextRef="i_2025-09-30_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="INF"
      id="c138417768"
      unitRef="USD">400000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="i_2024-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="INF"
      id="c138417769"
      unitRef="USD">380000</us-gaap:OtherCommitment>
    <gnpx:LicensingFeeAmount
      contextRef="i_2025-04-25_CounterpartyNameAxis-NyuMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417770"
      unitRef="USD">5000</gnpx:LicensingFeeAmount>
    <gnpx:LicensingFeeAmountAnnualFirstTwoYears
      contextRef="i_2025-04-25_CounterpartyNameAxis-NyuMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417771"
      unitRef="USD">35000</gnpx:LicensingFeeAmountAnnualFirstTwoYears>
    <gnpx:LicensingFeeAmountAnnualThirdYear
      contextRef="i_2025-04-25_CounterpartyNameAxis-NyuMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417774"
      unitRef="USD">25000</gnpx:LicensingFeeAmountAnnualThirdYear>
    <gnpx:LicensingFeeAmountAnnualFourthAndSubsequentYears
      contextRef="i_2025-04-25_CounterpartyNameAxis-NyuMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417776"
      unitRef="USD">50000</gnpx:LicensingFeeAmountAnnualFourthAndSubsequentYears>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2025-04-25_CounterpartyNameAxis-NyuMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="2"
      id="c138417779"
      unitRef="Pure">0.01</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2025-04-25_CounterpartyNameAxis-NyuMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="2"
      id="c138417780"
      unitRef="Pure">0.02</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:MilestonePayment
      contextRef="i_2025-04-25_CounterpartyNameAxis-NyuMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417781"
      unitRef="USD">400000</gnpx:MilestonePayment>
    <gnpx:ContractPaymentsIncurredAndPaid
      contextRef="d_2025-01-01_2025-09-30_CounterpartyNameAxis-NyuMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417782"
      unitRef="USD">5000</gnpx:ContractPaymentsIncurredAndPaid>
    <gnpx:LicensingFeeAmount
      contextRef="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417784"
      unitRef="USD">30000</gnpx:LicensingFeeAmount>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="2"
      id="c138417785"
      unitRef="Pure">0.01</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="2"
      id="c138417786"
      unitRef="Pure">0.03</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:MinimumAnnualRoyaltyFixedAmountFirstTwoYears
      contextRef="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417787"
      unitRef="USD">15000</gnpx:MinimumAnnualRoyaltyFixedAmountFirstTwoYears>
    <gnpx:MinimumAnnualRoyaltyFixedAmountThirdYearAndThereafter
      contextRef="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417790"
      unitRef="USD">30000</gnpx:MinimumAnnualRoyaltyFixedAmountThirdYearAndThereafter>
    <gnpx:ShareOfNonroyaltySublicenseIncomePercent
      contextRef="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="1"
      id="c138417792"
      unitRef="Pure">0.10</gnpx:ShareOfNonroyaltySublicenseIncomePercent>
    <gnpx:ShareOfNonroyaltySublicenseIncomePercent
      contextRef="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="1"
      id="c138417793"
      unitRef="Pure">0.40</gnpx:ShareOfNonroyaltySublicenseIncomePercent>
    <gnpx:CommercialSalesMilestoneAdditionalFdaRegulatoryApproval
      contextRef="i_2024-11-11_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417794"
      unitRef="USD">350000</gnpx:CommercialSalesMilestoneAdditionalFdaRegulatoryApproval>
    <gnpx:ContractPaymentsIncurredAndPaid
      contextRef="d_2025-07-01_2025-09-30_CounterpartyNameAxis-UniversityOfMichiganMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417797"
      unitRef="USD">30000</gnpx:ContractPaymentsIncurredAndPaid>
    <gnpx:LicensingFeeAmount
      contextRef="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417799"
      unitRef="USD">10000</gnpx:LicensingFeeAmount>
    <gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount
      contextRef="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417800"
      unitRef="USD">65000</gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount>
    <gnpx:AnnualMaintenanceFeeAfterYearThreeAmount
      contextRef="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417803"
      unitRef="USD">120000</gnpx:AnnualMaintenanceFeeAfterYearThreeAmount>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="3"
      id="c138417807"
      unitRef="Pure">0.015</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="2"
      id="c138417808"
      unitRef="Pure">0.03</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:AnnualRoyaltyPaymentPerYearMinimum
      contextRef="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417809"
      unitRef="USD">250000</gnpx:AnnualRoyaltyPaymentPerYearMinimum>
    <gnpx:ShareOfNonroyaltySublicenseIncomePercent
      contextRef="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="1"
      id="c138417811"
      unitRef="Pure">0.20</gnpx:ShareOfNonroyaltySublicenseIncomePercent>
    <gnpx:MilestonePayment
      contextRef="i_2025-02-17_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417812"
      unitRef="USD">4825000</gnpx:MilestonePayment>
    <gnpx:ContractPaymentsIncurredAndPaid
      contextRef="d_2025-07-01_2025-09-30_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417819"
      unitRef="USD">10000</gnpx:ContractPaymentsIncurredAndPaid>
    <gnpx:LicensingFeeAmount
      contextRef="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417820"
      unitRef="USD">10000</gnpx:LicensingFeeAmount>
    <gnpx:LicensingFeeAmountStaggeredUpfront
      contextRef="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417821"
      unitRef="USD">40000</gnpx:LicensingFeeAmountStaggeredUpfront>
    <gnpx:LicensingFeeAmountManagement
      contextRef="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417822"
      unitRef="USD">3000</gnpx:LicensingFeeAmountManagement>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="3"
      id="c138417823"
      unitRef="Pure">0.001</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="4"
      id="c138417824"
      unitRef="Pure">0.0025</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:AnnualRoyaltyPaymentPerYearMinimum
      contextRef="i_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417825"
      unitRef="USD">25000</gnpx:AnnualRoyaltyPaymentPerYearMinimum>
    <gnpx:ClinicalAndRegulatoryExpense
      contextRef="d_2025-05-02_2025-05-02_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417827"
      unitRef="USD">360000</gnpx:ClinicalAndRegulatoryExpense>
    <gnpx:ContractPaymentsIncurredAndPaid
      contextRef="d_2025-01-01_2025-09-30_CounterpartyNameAxis-UthealthHoustonMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c138417828"
      unitRef="USD">10000</gnpx:ContractPaymentsIncurredAndPaid>
    <gnpx:DevelopmentServicesAgreementExpectedTotalProjectCost
      contextRef="i_2023-03-31_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember"
      decimals="-5"
      id="c138417830"
      unitRef="USD">4500000</gnpx:DevelopmentServicesAgreementExpectedTotalProjectCost>
    <gnpx:ContractPaymentsReturnedToCompany
      contextRef="d_2024-06-30_2024-06-30_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember"
      decimals="-5"
      id="c138417831"
      unitRef="USD">1300000</gnpx:ContractPaymentsReturnedToCompany>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072296">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt;&#160;- Segment Reporting&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single segment (the &#x201c;Segment&#x201d;) for the purposes of assessing performance and making operating decisions. The CODM of the Segment is the Company&#x2019;s Chief&#160;Executive Officer. The Segment is focused on pioneering the discovery and development of gene therapies for use in patient populations with unmet medical needs.&#160;The accounting policies for the Segment are the same as those described in Note &lt;em style="font: inherit;"&gt;2,&lt;/em&gt; Summary of Significant Accounting Policies. The CODM assesses the performance of the Segment and decides how to allocate resources based on net loss that is reported on the&#160;condensed consolidated statements of operations. Further, the following represents information about segment loss and significant segment expenses:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 20%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 36%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical and regulatory&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,680,061&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,740,207&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,046,279&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,845,783&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Manufacturing&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;188,532&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;589,548&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,144,195&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,109,388&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;313,323&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;240,701&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;950,640&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;236,855&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative support&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,144,444&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,331,484&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,192,630&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,605,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-cash expenses(1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19,553&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;421,498&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;663,243&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,041,195&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,405&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,080&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,056&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;58,851&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Plus:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Other financing costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(455,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(455,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Realized and unrealized loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(629&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(262&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,115&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Segment and net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,799,240&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,315,987&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,438,742&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,780,702&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Includes&#160;$19,553 and $420,226&#160;of stock-based compensation expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively, and&#160;$0&#160;and&#160;$1,272 of depreciation and amortization expense for&#160;the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively. Includes&#160;$663,243 and&#160;$3,034,966 of stock-based compensation expense for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively, and&#160;$0 and&#160;$6,230 of depreciation and amortization expense for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively, inclusive of the amount stated in the preceding sentence.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072297">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 20%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Nine Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;September 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 36%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical and regulatory&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,680,061&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,740,207&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,046,279&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,845,783&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Manufacturing&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;188,532&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;589,548&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,144,195&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,109,388&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;313,323&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;240,701&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;950,640&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;236,855&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative support&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,144,444&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,331,484&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,192,630&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,605,217&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-cash expenses(1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19,553&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;421,498&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;663,243&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,041,195&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,405&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,080&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,056&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;58,851&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Plus:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Other financing costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(455,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(455,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Realized and unrealized loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(629&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(262&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,115&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Segment and net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,799,240&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,315,987&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,438,742&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,780,702&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417890"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417891"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417892"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417893"
      unitRef="USD">0</us-gaap:Revenues>
    <gnpx:ClinicalAndRegulatoryExpense
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417895"
      unitRef="USD">1680061</gnpx:ClinicalAndRegulatoryExpense>
    <gnpx:ClinicalAndRegulatoryExpense
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417896"
      unitRef="USD">1740207</gnpx:ClinicalAndRegulatoryExpense>
    <gnpx:ClinicalAndRegulatoryExpense
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417897"
      unitRef="USD">5046279</gnpx:ClinicalAndRegulatoryExpense>
    <gnpx:ClinicalAndRegulatoryExpense
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417898"
      unitRef="USD">5845783</gnpx:ClinicalAndRegulatoryExpense>
    <gnpx:ManufacturingCosts1
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417899"
      unitRef="USD">188532</gnpx:ManufacturingCosts1>
    <gnpx:ManufacturingCosts1
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417900"
      unitRef="USD">589548</gnpx:ManufacturingCosts1>
    <gnpx:ManufacturingCosts1
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417901"
      unitRef="USD">1144195</gnpx:ManufacturingCosts1>
    <gnpx:ManufacturingCosts1
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417902"
      unitRef="USD">1109388</gnpx:ManufacturingCosts1>
    <gnpx:ResearchAndDevelopmentExpense1
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417903"
      unitRef="USD">313323</gnpx:ResearchAndDevelopmentExpense1>
    <gnpx:ResearchAndDevelopmentExpense1
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417904"
      unitRef="USD">240701</gnpx:ResearchAndDevelopmentExpense1>
    <gnpx:ResearchAndDevelopmentExpense1
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417905"
      unitRef="USD">950640</gnpx:ResearchAndDevelopmentExpense1>
    <gnpx:ResearchAndDevelopmentExpense1
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417906"
      unitRef="USD">236855</gnpx:ResearchAndDevelopmentExpense1>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417907"
      unitRef="USD">1144444</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417908"
      unitRef="USD">1331484</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417909"
      unitRef="USD">4192630</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417910"
      unitRef="USD">6605217</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417911"
      unitRef="USD">19553</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417912"
      unitRef="USD">421498</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417913"
      unitRef="USD">663243</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417914"
      unitRef="USD">3041195</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417915"
      unitRef="USD">2405</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417916"
      unitRef="USD">8080</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417917"
      unitRef="USD">14056</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417918"
      unitRef="USD">58851</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417920"
      unitRef="USD">455549</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417921"
      unitRef="USD">-0</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417922"
      unitRef="USD">455549</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417923"
      unitRef="USD">-0</us-gaap:OtherNonoperatingExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417924"
      unitRef="USD">-183</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417925"
      unitRef="USD">-629</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417926"
      unitRef="USD">-262</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417927"
      unitRef="USD">-1115</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-07-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417928"
      unitRef="USD">3799240</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-07-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417929"
      unitRef="USD">4315987</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417930"
      unitRef="USD">12438742</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-09-30_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="INF"
      id="c138417931"
      unitRef="USD">16780702</us-gaap:NetIncomeLoss>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-07-01_2025-09-30"
      decimals="INF"
      id="c138417862"
      unitRef="USD">19553</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417863"
      unitRef="USD">420226</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:Depreciation
      contextRef="d_2025-07-01_2025-09-30"
      decimals="-3"
      id="c138417866"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-07-01_2024-09-30"
      decimals="INF"
      id="c138417867"
      unitRef="USD">1272</us-gaap:Depreciation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-09-30"
      decimals="INF"
      id="c138417870"
      unitRef="USD">663243</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138417871"
      unitRef="USD">3034966</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:Depreciation
      contextRef="d_2025-01-01_2025-09-30"
      decimals="-3"
      id="c138417874"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-09-30"
      decimals="INF"
      id="c138417875"
      unitRef="USD">6230</us-gaap:Depreciation>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072298">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;&#160;- Subsequent Events&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The Company has evaluated subsequent events through the filing of this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and determined that there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; recognized subsequent events that have occurred that would require adjustments to the Company's disclosures in the condensed consolidated financial statements. The following are&#160;nonrecognized subsequent events through the filing of this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt; Reverse Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 21, 2025, &lt;/em&gt;Genprex completed a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-50 reverse stock split (&lt;em style="font: inherit;"&gt;&#x201c;2025&lt;/em&gt;&#160;Reverse Split&#x201d;) of its issued and outstanding shares of common stock. The &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&#160;Reverse Split did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; change the number of authorized shares of common stock or par value. All references in these financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&#160;Reverse Split (See Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;&#x2013; Equity &#x2013; Reverse Stock Split).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Share Issuances&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 1,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; Genprex issued&#160;100 shares of its common stock to the Chairman of its Scientific Advisory Board&#160;in consideration for services. From &lt;em style="font: inherit;"&gt; October&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; through the date of filing of this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q, the Company has sold 326,750&#160;shares of its common stock to Lincoln Park as purchase shares for aggregate net proceeds to the Company totaling $1,434,139&#160;under the&#160;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt; ELOC Facility.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt; October 2025&#160;&lt;/em&gt;Registered Direct Offerings&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 24, 2025, &lt;/em&gt;Genprex completed a registered direct offering priced at-the-market under Nasdaq rules (the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Registered Direct Offering I&#x201d;), pursuant to which the Company issued an aggregate of&#160;243,622 shares of common stock at a purchase price of&#160;$11.21 per share. In a concurrent private placement (the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Private Placement I&#x201d;, and together with the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Registered Direct Offering I, the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Financing I&#x201d;), the Company issued warrants (the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Private Warrants I&#x201d;) exercisable for up to an aggregate of 487,244 shares of common stock (the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Private Warrant Shares I&#x201d;) at an exercise price of $11.00 per share. The&#160;&lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants I are exercisable immediately upon issuance and will expire 24 months from the effective date of a resale registration statement registering the resale of all of the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrant Shares I.&#160;Also, the Company agreed to issue to H.C. Wainwright &amp;amp; Co., LLC (the &#x201c;Placement Agent&#x201d;) or its designees warrants to purchase up to an aggregate of 14,617 shares of common stock.&#160;The warrants issued to the Placement Agent or its designees have substantially the same terms as the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants I except that the warrants issued to the Placement Agent or its designees have an exercise price of $14.0125 per share and a termination date that will be the earlier of (i) 24 months from the effective date of the resale registration statement covering the resale of the shares of common stock underlying the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrant Shares I and (ii) &lt;em style="font: inherit;"&gt; October 23, 2030. &lt;/em&gt;The net proceeds of the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Financing I, after deducting the placement agent&#x2019;s fees and expenses and other estimated &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Registered Direct Offering I expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants I, were approximately $2.5 million. Additionally, if the holders of &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants I exercise such warrants in full, the Company would receive additional gross proceeds of approximately $5.4 million.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; October 29, 2025, &lt;/em&gt;Genprex completed a registered direct offering priced at-the-market under Nasdaq rules (the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Registered Direct Offering II&#x201d;), pursuant to which the Company issued an aggregate of&#160;377,780 shares of common stock at a purchase price of&#160;$9.00 per share. In a concurrent private placement (the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Private Placement II&#x201d;, and together with the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Registered Direct Offering II, the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Financing II&#x201d;), the Company issued warrants (the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Private Warrants II&#x201d;) exercisable for up to an aggregate of 755,560 shares of common stock (the &lt;em style="font: inherit;"&gt; &#x201c;October 2025 &lt;/em&gt;Private Warrant Shares II&#x201d;) at an exercise price of $8.75 per share. The&#160;&lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants II are exercisable immediately upon issuance and will expire 24 months from the effective date of a resale registration statement registering the resale of all of the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrant Shares II.&#160;Also, the Company agreed to issue to H.C. Wainwright &amp;amp; Co., LLC (the &#x201c;Placement Agent&#x201d;) or its designees warrants to purchase up to an aggregate of 22,667 shares of common stock.&#160;The warrants issued to the Placement Agent or its designees have substantially the same terms as the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants II except that the warrants issued to the Placement Agent or its designees have an exercise price of $11.25 per share and a termination date that will be the earlier of (i) 24 months from the effective date of the resale registration statement covering the resale of the shares of common stock underlying the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrant Shares II and (ii) &lt;em style="font: inherit;"&gt; October 28, 2030.&#160;&lt;/em&gt;In addition, in connection with any future exercise of the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants II, the Company has agreed to (A) pay the Placement Agent (i) a cash fee equal to 7.0% of the aggregate gross exercise price paid in cash with respect to the exercise of such warrants and (ii) a management fee equal to 1.0% of the aggregate gross exercise price paid in cash with respect to the exercise of such warrants and (B) issue to Placement Agent or its designees additional placement agent warrants to purchase that number of shares equal to 6.0% of the aggregate number of shares of common stock underlying such &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants II that have been exercised. The net proceeds of the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Financing II, after deducting the placement agent&#x2019;s fees and expenses and other estimated &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Registered Direct Offering II expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants II, were approximately $3.1 million. Additionally, if the holders of &lt;em style="font: inherit;"&gt; October 2025 &lt;/em&gt;Private Warrants II exercise such warrants in full, the Company would receive additional net&#160;proceeds of approximately $6.1&#160;million.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;At-The-Market Offering&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; November 10, 2025, &lt;/em&gt;Genprex filed a prospectus supplement for up to $11.495 million of common stock with respect to the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; ATM Facility, which amended the previously filed prospectus supplements to update the aggregate market value of the Company&#x2019;s outstanding common stock held by non-affiliates (&#x201c;public float&#x201d;) and indicate that, since the Company&#x2019;s public float is above &lt;em style="font: inherit;"&gt;$75.0&lt;/em&gt; million, the Company is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer subject to the sales limitations of General Instruction &lt;em style="font: inherit;"&gt;I.B.6&lt;/em&gt; of Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; with respect to its currently effective shelf Registration Statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; (File &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;333&lt;/em&gt;-&lt;em style="font: inherit;"&gt;271386&lt;/em&gt;) pursuant to which &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; ATM Facility sales are effectuated.&#160; From &lt;em style="font: inherit;"&gt; October 1, 2025 &lt;/em&gt;through the date of filing of this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q, the Company sold 242,537&#160;shares of common stock for aggregate net proceeds of $1,006,740&#160;under the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; ATM Facility.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2025-10-21_2025-10-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417938"
      unitRef="Pure">50</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2025-10-01_2025-10-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c138417945"
      unitRef="Share">100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-10-01_2025-10-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417949"
      unitRef="Share">326750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-10-01_2025-10-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2025ElocFacilityMember"
      decimals="INF"
      id="c138417950"
      unitRef="USD">1434139</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-10-24_2025-10-24_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2024RegisteredDirectOffering1Member"
      decimals="INF"
      id="c138417952"
      unitRef="Share">243622</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2025-10-24_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2024RegisteredDirectOffering1Member"
      decimals="INF"
      id="c138417953"
      unitRef="USDPerShare">11.21</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-10-24_ClassOfWarrantOrRightAxis-October2025PrivateWarrants1Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417954"
      unitRef="Share">487244</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-10-24_ClassOfWarrantOrRightAxis-October2025PrivateWarrants1Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417955"
      unitRef="USDPerShare">11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-10-24_ClassOfWarrantOrRightAxis-October2025PrivateWarrants1Member_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c138417956">P24M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-10-24_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417957"
      unitRef="Share">14617</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-10-24_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417958"
      unitRef="USDPerShare">14.0125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-10-24_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c138417959">P24M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <gnpx:ProceedsFromIssuanceOfWarrantsGross
      contextRef="d_2025-10-24_2025-10-24_ClassOfWarrantOrRightAxis-October2025PrivateWarrants1Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c138417960"
      unitRef="USD">2500000</gnpx:ProceedsFromIssuanceOfWarrantsGross>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2025-10-24_2025-10-24_ClassOfWarrantOrRightAxis-October2025PrivateWarrants1Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c138417961"
      unitRef="USD">5400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-10-29_2025-10-29_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2025RegisteredDirectOffering2Member"
      decimals="INF"
      id="c138417962"
      unitRef="Share">377780</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2025-10-29_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2025RegisteredDirectOffering2Member"
      decimals="INF"
      id="c138417963"
      unitRef="USDPerShare">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-10-29_ClassOfWarrantOrRightAxis-October2025PrivateWarrants2Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417964"
      unitRef="Share">755560</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-10-29_ClassOfWarrantOrRightAxis-October2025PrivateWarrants2Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417965"
      unitRef="USDPerShare">8.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-10-29_ClassOfWarrantOrRightAxis-October2025PrivateWarrants2Member_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c138417966">P24M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-10-29_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417967"
      unitRef="Share">22667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-10-29_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c138417968"
      unitRef="USDPerShare">11.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-10-29_ClassOfWarrantOrRightAxis-PlacementAgentWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c138417969">P24M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <gnpx:SaleOfStockCashFee
      contextRef="i_2025-10-29_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2025RegisteredDirectOffering2Member"
      decimals="2"
      id="c138417970"
      unitRef="Pure">0.07</gnpx:SaleOfStockCashFee>
    <gnpx:SaleOfStockManagementFee
      contextRef="i_2025-10-29_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2025RegisteredDirectOffering2Member"
      decimals="2"
      id="c138417971"
      unitRef="Pure">0.01</gnpx:SaleOfStockManagementFee>
    <gnpx:SaleOfStockPurchasableWarrants
      contextRef="i_2025-10-29_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-October2025RegisteredDirectOffering2Member"
      decimals="2"
      id="c138417972"
      unitRef="Pure">0.06</gnpx:SaleOfStockPurchasableWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2025-10-29_2025-10-29_ClassOfWarrantOrRightAxis-October2025PrivateWarrants2Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c138417973"
      unitRef="USD">3100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <gnpx:ProceedsFromIssuanceOfWarrantsGross
      contextRef="d_2025-10-29_2025-10-29_ClassOfWarrantOrRightAxis-October2025PrivateWarrants2Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c138417974"
      unitRef="USD">6100000</gnpx:ProceedsFromIssuanceOfWarrantsGross>
    <gnpx:EquityIssuanceMaximumAmountAvailableForIssuance
      contextRef="d_2025-11-10_2025-11-10_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="-3"
      id="c138417975"
      unitRef="USD">11495000</gnpx:EquityIssuanceMaximumAmountAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-10-01_2025-11-14_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417987"
      unitRef="Share">242537</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-10-01_2025-11-14_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2023AtmFacilityMember"
      decimals="INF"
      id="c138417988"
      unitRef="USD">1006740</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2025-01-01_2025-09-30" id="c3072299">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;b&gt;&lt;a href="#" id="item5" title="item5"&gt;&lt;/a&gt;Item &lt;em style="font: inherit;"&gt;5.&lt;/em&gt; Other Information&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 18pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Rule&lt;/span&gt;&lt;/i&gt;&lt;span style="text-decoration: underline; "&gt;&#160;&lt;/span&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/span&gt;&lt;/i&gt;&lt;span style="text-decoration: underline; "&gt;&#160;&lt;/span&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Trading Arrangements and Non-Rule&lt;/span&gt;&lt;/i&gt;&lt;span style="text-decoration: underline; "&gt;&#160;&lt;/span&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&lt;/span&gt;&lt;/i&gt;&lt;span style="text-decoration: underline; "&gt;&#160;&lt;/span&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Trading Arrangements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;"&gt;During the fiscal quarter ended&#160;&lt;em style="font: inherit;"&gt; September 30, 2025&lt;/em&gt;, &lt;span style="-sec-ix-hidden:c138417996"&gt;&lt;span style="-sec-ix-hidden:c138417997"&gt;&lt;span style="-sec-ix-hidden:c138417998"&gt;&lt;span style="-sec-ix-hidden:c138417999"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our officers or directors, as those terms are defined in Rule&#160;&lt;em style="font: inherit;"&gt;16a&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;(f), adopted or terminated a &#x201c;Rule&#160;&lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;trading arrangement&#x201d; or a &#x201c;non-Rule&#160;&lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;trading arrangement,&#x201d; as those terms are defined in Item&#160;&lt;em style="font: inherit;"&gt;408&lt;/em&gt;&#160;of Regulation S-K.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;"&gt;&#160;&lt;/p&gt;
  </ecd:MtrlTermsOfTrdArrTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c138417912"
          xlink:label="c138417912"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c138417913"
          xlink:label="c138417913"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c138417911"
          xlink:label="c138417911"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c138417914"
          xlink:label="c138417914"
          xlink:type="locator"/>
        <link:footnote id="f9acfaad8-05e5-4309-9321-5b92ec147637" xlink:label="f9acfaad8-05e5-4309-9321-5b92ec147637" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Includes $19,553 and $420,226 of stock-based compensation expense for the three months ended  September 30, 2025 and 2024, respectively, and $0 and $1,272 of depreciation and amortization expense for the three months ended  September 30, 2025 and 2024, respectively. Includes $663,243 and $3,034,966 of stock-based compensation expense for the nine months ended September 30, 2025 and 2024, respectively, and $0 and $6,230 of depreciation and amortization expense for the nine months ended September 30, 2025 and 2024, respectively, inclusive of the amount stated in the preceding sentence</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c138417912"
          xlink:to="f9acfaad8-05e5-4309-9321-5b92ec147637"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c138417913"
          xlink:to="f9acfaad8-05e5-4309-9321-5b92ec147637"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c138417911"
          xlink:to="f9acfaad8-05e5-4309-9321-5b92ec147637"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c138417914"
          xlink:to="f9acfaad8-05e5-4309-9321-5b92ec147637"
          xlink:type="arc"/>
        <link:footnote id="f9f83e487-9969-4889-996c-35875a86b15e" xlink:label="f9f83e487-9969-4889-996c-35875a86b15e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Includes $19,553 and $420,226 of stock-based compensation expense for the three months ended  September 30, 2025 and 2024, respectively, and $0 and $1,272 of depreciation and amortization expense for the three months ended  September 30, 2025 and 2024, respectively. Includes $663,243 and $3,034,966 of stock-based compensation expense for the nine months ended September 30, 2025 and 2024, respectively, and $0 and $6,230 of depreciation and amortization expense for the nine months ended September 30, 2025 and 2024, respectively, inclusive of the amount stated in the preceding sentence.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c138417912"
          xlink:to="f9f83e487-9969-4889-996c-35875a86b15e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c138417913"
          xlink:to="f9f83e487-9969-4889-996c-35875a86b15e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c138417911"
          xlink:to="f9f83e487-9969-4889-996c-35875a86b15e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c138417914"
          xlink:to="f9f83e487-9969-4889-996c-35875a86b15e"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
